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General introduction
Parts of this introduction are based on: 
Sarcoidosis: changing insights in therapy
Kamphuis LS, van Laar JA, Kuijpers RW, 
Missotten T, Thio HB, van Hagen PM
Ned Tijdschr Geneeskd. 2010;154:A1685
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Introduction
Sarcoidosis is a granulomatous disorder of unknown cause, affecting 
multiple organs. It was first described in 1877 as a skin disease by a 
dermatologist, Jonathan Hutchinson (1). However, the most famous 
synonym worldwide for sarcoidosis is Besnier-Boeck-Schaumann disease (2).
 Mostly sarcoidosis develops before the age of 50 years, with an 
incidence peaking at 20 to 39 years (3). The worldwide prevalence 
varies from 2 to 80 per 100,000 (4). In the Netherlands the prevalence is 
estimated to be 50 per 100,000 (5). However, in 30-60% of the cases the 
prevalence may be underestimated by the asymptomatic signs of the 
disease (5). In Afro-Americans the incidence is three times higher compared to 
Caucasians and it is also more likely to be chronic and fatal in Afro-Americans (3, 6). 
 Seasonal clustering of sarcoidosis has been reported 
between March and July and occupation clustering was recorded in 
health care workers, naval aircraft servicemen and fire fighters (7).
Immunopathogenesis and genetics
It is presumed that granulomas play a central role in the pathogenesis of 
sarcoidosis. In normal conditions granulomas are produced to lock up 
pathogens leading to a protection of the surrounded tissue against an 
inflammatory reaction. The hypothesis in sarcoidosis is that granulomas 
are formed by an interaction between antigen presenting cells (APC) and 
activated T-lymphocytes, mainly CD4+ T cells. This leads to a release of 
cytokines, (interleukin(IL)-2 and interferon (IFN)-γ), who are triggering 
macrophages to produce tumor necrosis factor-α (TNF-α) and strengthen the local 
inflammation response by releasing a cascade of several cytokines (Figure 1) (8).
 The clustering written above support the idea 
that an agent might be the trigger to induce sarcoidosis. 
However, no agent has been identified as the cause of sarcoidosis, so far. 
 In the 1990’s large numbers of B-lymphocytes were found in 
intergranulomatous areas of lymph nodes in sarcoidosis patients (9). 
However, until now the role of the B-lymphocyte in sarcoidosis remains 
open. B-lymphocytes are responsible for the humoral response. They 
contribute to the immune system by production of antigen-specific antibodies. 
 TNF-α stimulates the differentiation of monocytes into macrophages 
and the differentiation of macrophages into epithelioid cells, where after giant
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cells are produced. Those cells are generated because of the junction of 
epithelioid cells (10). Treated sarcoidosis patients show a spontaneous high 
release of TNF-α in alveolar macrophages compared to a control group 
(11). That is why TNF-α seems to play a central role in the pathogenesis of 
sarcoidosis. Another argument that TNF-α plays a major role are the recent 
results of genetic analysis in sarcoidosis patients. De presence of 
TNF-α-G308A-allel in HLA-DRB1*03 positive patients is predictive for a better 
prognosis in pulmonary sarcoidosis (12). Furthermore, there is a connection 
between TNF-α-G308A and HLA-DRB1*03 expression in patients with acute 
sarcoidosis i.e. Löfgren’s syndrome. HLA-DRB1*03 positive patients with this 
syndrome have a higher chance to recover than HLA-DRB1*03 negative 
patients (13). 
 Mutations which can lead to sarcoidosis are found in child-
ren younger than four years and is called “early onset sarcoidosis (EOS)” 
and the “Blau syndrome” (14). These rare autosomal dominant disorders 
with arthritis and granulomatous inflammation of the eyes and skin is 
caused by mutations in the nucleotide binding oligomerisationdomain 
(NOD)-2 gene. This leads to a hyperreactive defense mechanism with 
granuloma production in which TNF-α and IFN-γ seem to play a 
major role (14, 15).
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Figure 1. The hypothesized immunopathogenesis in sarcoidosis.
Clinical manifestation
The clinical presentation of sarcoidosis depends on which organ is affected. Given 
the fact that any organ can be involved, the presentation varies widely in symptoms 
and clinical findings (16). Nonspecific symptoms like fatigue, weight loss and 
fever may be indicative for active sarcoidosis. Acute presentation, i.e., Löfgren’s 
syndrome, presents with acute arthritis, erythema nodosum and bilateral 
hilar lymphadenopathy. Heerfordt’s syndrome is another rare syndrome 
of sarcoidosis and presents with a triad of facial nerve palsy, 
uveitis and parotid gland enlargement (17). 
Pathogens
                           T-cell              APC
IL-2, IL-12, TNF-α, IFN-γ
Granuloma
      Resolution                       Fibrosis
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Pulmonary involvement
The lung is involved in the majority of patients and symptoms like 
dyspnea and cough usually implies active disease. Depending on the 
severity of the inflammation in the lung, pulmonary function tests may 
reveal restricted lung volumes and/or impaired diffusion capacity (18).
Skin involvement
Cutaneous manifestations occur in about 25% of sarcoidosis patients (19). 
Patients presenting with only sarcoid like lesions on the skin will mostly be 
found to develop other evidence of systemic sarcoidosis (20). Common signs of 
skin involvement are maculopapular lesions, lupus pernio, cutaneous or
subcutaneous nodules and infiltrative scars (19, 20). Cutaneous involvement is 
more common in patients of African descent than in white (21). Lupus pernio 
seems to be associated with chronic sarcoidosis and a worse prognosis (23). 
The most common nonspecific lesion is erythema nodosum. This occurs 
in 3% to 34% of patients with systemic sarcoidosis (19). In contrast 
to lupus pernio, patients with erythema nodosum tend to have a good 
prognosis and not go on to chronic disease (19). 
Ocular involvement
The frequency of ocular involvement differs between 10% to 50%, and
includes extraocular disorders such as lacrimal gland swelling or sicca 
syndrome (23). Intraocular involvement seen as uveitis is a significant concern 
because it is likely to reduce the vision and to deteriorate the quality of life. 
All patients suspected for sarcoidosis should be referred to an ophthalmologist.
Neurological manifestations
Neurosarcoidosis, which is thought to occur in less than 10% of the patients, 
has a predilection for the base of the brain. However, any part of the central 
or peripheral nervous system may be involved (24, 25). The diagnosis of
neurosarcoidosis is often very difficult, especially in patients who lack 
either pulmonary or systemic manifestations of sarcoidosis. About 50% of 
patients with nervous system sarcoidosis have facial nerve palsy (26). Peripheral 
nervous system involvement may cause muscle weakness, atrophy, sensory 
disturbance or deep tendon-reflex loss in the distribution of the affected nerve (27).
Cardiac involvement
Cardiac involvement is the leading cause of death in sarcoidosis. An electrocar-
diography should therefore be performed at diagnosis (24). In a recent report 
Pathogens
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the incidence of cardiac sarcoidosis was 2.3% (6). The most frequent 
cardiac manifestations are arrhythmias, sudden death and congestive 
heart failure, but uncommon manifestations have also been reported. 
Hypercalcemia
Hypercalcemia is a known feature in sarcoidosis with a prevalence of 
5 to 11% (28, 29). Activated macrophages in sarcoid granulomas are 
capable to upregulate extrarenal 1α-hydroxylase, the enzyme which converts 
25-hydroxy vitamin D (25-(OH)D) to its active form, 1,25-dihydroxy 
vitamin D (1,25(OH)2D). This can result in hypercalcemia (30). Other 
mechanisms for hypercalcemia in sarcoidosis are expression of parathyroid 
hormone-related protein (PTH-rP) in sarcoid macrophages what may exert an 
autocrine action of 1α-hydroxylase activity and increased levels of serum IFN-γ
(31-34). IFN-γ stimulates the production of 1,25(OH)2D by alveolar 
macrophages (35).
Diagnostic procedures
Sarcoidosis is a diagnosis of exclusion. There exist neither a pathognomonic 
clinical feature nor a perfect diagnostic test. Missed diagnosis and overdiagnosis 
are therefore common. Currently the diagnosis of sarcoidosis is based on the 
criteria as proposed by the American Thoracic Society, European 
Respiratory Society and World Association of Sarcoidosis 
and Other Granulomatous Disorders (36). This means histological 
confirmation of non-caseating granulomas, clinical signs of activity and 
radiological pictures are compatible with sarcoidosis. 
 Among serum markers in sarcoidosis, serum angiotensin converting 
enzyme (ACE) is the most used (36). It is produced by epitheloid cells and 
alveolar macrophages and serum levels of ACE are thought to reflect the 
extent of granulomatous inflammation (36). However, elevated levels of serum 
ACE can be found in other medical conditions as well. Its sensitivity is low 
(55%), but when the diagnosis sarcoidosis is confirmed the specificity is 99% 
(37). Therefore it is suggested to be useful for treatment monitoring (38, 39). 
 Elevated levels of soluble IL-2 receptor (sIL-2R) in serum have been 
shown to be associated with active disease (40). IL-2 receptors are found on 
the surface of T- and B-lymphocytes, monocytes and macrophages (41-43). 
Its soluble form is associated with cellular immune reactions and might
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therefore be increased in sarcoidosis. The bronchoalveolar lavage in 
sarcoidosis patients reveals an increased number of T-lymphocytes 
expressed to an increased CD4+/CD8+ ratio (44). Despite their diagnostic value, 
the number of lymphocytes and the CD4+/CD8+ ratio do not have a predictive 
value. 
 Visualization techniques in sarcoidosis are most common 
a chest X-ray and computed tomography (CT) – scan. Other used 
techniques are the Fluorine-18 fluorodeoxyglucose positron emission 
tomography (18F-FDG PET) and the somatostatin receptor scintigraphy (SRS). 
Treatment
Treatment of symptoms is essential in sarcoidosis. Systemic treatment is 
often started when there are signs of organ damage or invalidating 
clinical signs. The first step of symptom treatment are local 
corticosteroids, NSAID’s or other pain medication. Hydroxychloroquine, 
an anti malaria drug with immunomodulatory effects, may prevent for organ 
damage (4). Treatment with corticosteroids is indicated by severe general signs, 
vital organ damage or hypercalcemia (4, 6, 11). In case of insufficient therapeu-
tic efficacy of side effects other immunosuppressives could be used, see Table 1.
 Corticosteroids have an extensive immunosuppressive effect 
under which the inhibition of T-lymphocytes TNF-α. There are several 
conventional immunosuppressives with a comparable mechanism. For example 
pentoxyifylline is suppressing the release of TNF-α by alveolair macrophages. 
However, the used dosage of pentoxifylline was causing a lot of gastrointestinal 
side effects (45). 
 If a patient has sarcoidosis for more than two years, it 
is called chronic sarcoidosis (5). A dosage of prednisolon under 
7.5 mg/day in chronic sarcoidosis can be continued. In cases of higher 
dosages it is indicated to switch to another immunosuppresive, like 
methotrexate, azathioprine, cyclophosphamide or mycofenolate mophetil. 
The next step in the treatment of chronic sarcoidosis are TNF-α blockers (11). 
The development of TNF-α blockers was the beginning of a new 
chapter in the treatment of sarcoidosis. TNF-α is probably the most 
important cytokine in sarcoidosis and inhibition of this cytokine has 
besides in sarcoidosis also in a lot of other systemic diseases a positive effect (4). 
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Currently there are four TNF-α blockers available: infliximab, 
adalimumab, etanercept and golimumab. Infliximab and adalimumab 
propably induce apoptosis of TNF-α binding cells, what contributes to the 
inhibition of granuloma formation. Infliximab is the
most investigated of this four and has shown to be effective in 
other inflammatory diseases (46). Recently, the TNF-α blocker infliximab 
demonstrated significant clinical benefit in large cohorts of patients with 
pulmonary manifestations of sarcoidosis (47, 48). In two 
double-blinded randomized, and placebo controlled trials of patients with 
pulmonary sarcoidosis a favorable clinical response was demonstrated (49, 50). 
Etanercept has been reported effective in case reports, but the only trial so far 
resulted in detoriation of almost a third of the patients with acute pulmonary 
sarcoidosis (51-53). Adalimumab could be an important additional option in 
the treatment with biologicals. 
 Other biologicals available for the treatment of sarcoidosis 
are rare. There are a few cases of a positive effect of anti B-lymphocyte therapy, 
i.e. rituximab (anti-CD20).  
Table 1. Current immunosuppressive treatment in sarcoidosis.
Medication Dose
Glucocorticosteriods
Prednisone start 5-40 mg/day
maintenance <10 mg/day
Anti malaria drugs
Hydroxychloroquine 200-400 mg/day
Cytotoxic medication
Azathioprine 50-150 mg/day
Cyclophosphamide 50-150 mg/day oral
500-1500 mg Q2-4W i.v.
Methotrexate 10-25 mg/weekly
Sodium mycophenolate/mycophenolate mofetil 720 mg/1000 mg twice daily
Cytokine modulating medication
Infliximab 50-10 mg/kg Q4-8W
Adalimumab 40-80 mg Q1-2W
Thalidomide 50-100 mg/day
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Prognosis
The prognosis of acute sarcoidosis (Löfgren’s syndrome) is good 
and spontaneous resolution frequently occurs within two years. The 
mortality rate of sarcoidosis is approximately 5% (54). In more than 50% 
of the patients a spontaneous remission is seen within three years (4). 
 Sarcoidosis can be classified in five stages according to the 
Scadding system with chest X-rays (55, 56). Stage 0, normal appearance; 
stage I, bilateral hilar lymphadenopathy alone; stage II, bilateral hilar 
lymphadenopathy and parenchymal shadowing; stage III, parenchymal 
shadowing alone; stage IV, fibrosis. The remission rate is related to the 
radiographic stage, but may vary due to the different ethnic backgrounds 
(3, 57-60). Approximately 45-80% of the patients with stage I will recover from 
sarcoidosis, which is 30-70% in stage II, 10-20% in stage III and 0% in stage IV. 
Aims of this thesis
Sarcoidosis is a granulomatous multisystem disease of unknown 
origine what makes it difficult to manage because of a lack of disease 
activity criteria, specific sarcoid biomarkers, and limited therapeutic 
possibilities. In this thesis we have focused on B cells in the pathophysiology 
of sarcoid granulomas in order to detect new disease targets, imaging and 
biomarkers in sarcoidosis, and new therapeutic approaches in sarcoidosis. 
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ME, Batstra MR, van Hagen PM, van Laar JA
Am J Respir Crit Care Med. 2013;187:406-416
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Abstract
Rationale
Recent observations of abnormal immunoglobulin responses
and case reports describing successful B-cell ablabtive therapy
suggest involvement of B cells in the pathogenesis of sarcoidosis. 
Objectives
To investigate how abnormal B-cell maturation and function
in patients with sarcoidosis contribute to disease.
Methods
Patients with sarcoidosis (n = 32) were included for detailed analysis
by immunohistochemistry of tissue, flow cytometry of blood B-cell
subsets, and serum immunoglobulin levels. Vaccination responses
in patients with sarcoidosis to influenza virus and encapsulated
bacteria and molecular analysis of immunoglobulin responses.
Measurements and main results
Perigranuloma localization of IgA-producing plasma cells and numerous
B cells were found in affected tissues. Total blood B-cell numbers were 
normal, CD27+ memory B cells were significantly reduced, and 
CD27-IgA+ B cells were significantly increased; the results are normalized
in patients treated with TNF-α blockers. Despite this, patients had normal 
serum immunoglobulin levels and normal antigen-specific 
immunoglobulin responses. IgA and IgG transcripts, however, showed
high frequencies of somatic hypermutations and increased usage of 
ownstream IgG subclasses, suggestive for prolonged or repetitive responses.
Conclusions
The large B-cell infiltrates in granulomatous tissue and increased molecular
signs of antibody maturation are indicative of direct involvement of B cells 
in local inflammatory processes in patient with sarcoidosis. Moreover, 
CD27-IgA+ B cells could be a marker for treatment with TNF-α blockers. 
These findings of B cells as ermerging key players provide a rationale for 
a systemic study on B-cell ablative therapy in patients with sarcoidosis. 
Pathogenesis
23
Introduction
B cells are emerging as key players in several systemic autoimmune diseases 
that were generally considered T cell mediated, such as rheumatoid 
arthritis and granulomatosis with polyangiitis (1, 2). Sarcoidosis is a 
multisystem disorder of unknown etiology and is also considered T cell 
driven (3-5). The hallmark of sarcoidosis is the occurrence of non-caseating 
granulomas characterized by epithelioid- and CD4+ T cells surrounded by 
fibroblasts and CD8+ T cells accompanied by high tumor necrosis factor (TNF)-α 
levels (6, 7). In more advanced stages, a restricted repertoire of T cell receptors 
and oligoclonal T cell expansions suggest selective immunological activation (3). 
 Despite proven involvement of cellular immunity, several 
observations suggest abnormal B cell responses in sarcoidosis. These 
concern circulating immune complexes, hypergammaglobulinemia, 
autoantibody production, anergy and reduced frequencies of circulating 
CD27+ memory B cells (8-12). Moreover, treatment with B cell ablative therapy 
with the chimeric anti-CD20 antibody rituximab yields clinical improvement of 
sarcoidosis patients (13-16). Rituximab targets CD20, which is expressed on the 
surface of naive and memory B cells, but not on plasma cells (1). This suggests 
that naive and/or memory B cells play a pathophysiological role in sarcoidosis. 
 B cell involvement has been reported in other granulomatous 
diseases. In granulomatosis with polyangiitis, B cells are present in 
pathological lesions and B cell ablative therapy is highly effective (1). 
Furthermore, reduced numbers of blood memory B cells are observed 
in a granulomatous subgroup of patients with hypogammaglobulinemia 
(common variable immunodeficiency; CVID) (17-19). Recent findings reveal 
that in tuberculosis, a classical infectious granulomatous disease, B cells are 
present and participate in the development of tuberculous granulomas (20, 21). 
 After maturation from hematopoietic stem cells and generation of a 
functional immunoglobulin, B cells migrate from bone marrow to blood and 
peripheral lymphoid organs (22). B cells that specifically recognize antigen 
in lymphoid tissue with their specific surface immunoglobulin mature into 
immunoglobulin-secreting plasma cells and memory B cells (23). So, recirculating 
memory B cells in blood can reflect local responses (23). Detailed flow cytometric 
and molecular analyses of 6 blood memory B cell subsets and their origins from 
T cell dependent and T cell independent responses are recently described (24). 
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In this study, we phenotyped B cells in granulomas and blood of patients 
with sarcoidosis and studied their molecular functional characteristics and 
immunoglobulin responses to T cell-dependent and T cell-independent 
antigens. Although immunoglobulin responses appear normal, the 
presence of B cells in granulomas and altered memory B cell formation 
suggest pathophysiological involvement of B cells in sarcoidosis. Some of the 
results of these studies have been previously reported in the form of posters (25-27).
Material and methods
Patients
Diagnostic work-up, detailed studies of blood, tissue biopsies and 
vaccinations of 32 patients with sarcoidosis (Table 1) and control 
subjects were performed with informed consent according to the Declaration 
of Helsinki and guidelines of the Medical Ethics Committee of Erasmus MC. 
Immunohistochemistry of tissue biopsies
Lymphocytes were studied in biopsies containing granulomas of 17 
therapy-naive patients with sarcoidosis from various affected tissues, 
including lymph nodes of inguinal, axillary, and neck glands; skin; liver; 
heart; and bone marrow. Tissue slides were stained with hematoxylin and 
eosin and antibodies recognizing CD4 (SD35; Ventana, Tucson, 
Arizona), CD3 (UCHT1), CD8 (C8/144B), CD20 (L26), CD79a (JCB117) and IgG 
(A57H), IgA (polyclonal rabbit antibody; all from Dako Cytomation, Glostrup, 
Denmark), CD5 (4C7; Novocastra, Newcastle, UK), PAX5 (rabbit polyclonal 
antibody; Thermo Scientific, Waltham, MA), CD138 (B-A38; IQ Products, 
Groningen, The Netherlands), and IgM (IgM88; Biogenex, Fremont, CA). 
Flow cytometric analysis of blood lymphocytes and B cell subsets
Absolute counts of blood CD4 and CD8 T cells, CD16/56+ natural killers
cells, and CD19+ B cells were obtained with a diagnostic lyse-no-wash 
protocol. Eight-color flow cytometric immunophenotyping was performed as 
described previously to detect transitional, naive mature, CD21lowCD38low, 
plasma cell and memory B cell subsets (Figure 2) (24) and to detect CXCR3 
expression levels using monoclonal antibodies against CD24-PB (ExBio), 
CD45-PO (Invitrogen, Carlsbad, CA), IgM-FITC, IgD-PE, IgG-PE, IgA-PE (all goat 
polyclonal from SBA, Washington, DC), CD19-PerCP-Cy5.5, CD21-PE-Cy7, 
CD27-APC, CD183-APC, CD38-APC-H7 and IgD-biotin (all from 
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BD Biosciences, Franklin Lakes, NJ) (24). Biotinylated antibodies were 
detected with Streptavidin PE-Cy7 (eBioscience, San Diego, CA). 
 Intracellular cytokine staining were performed on post-Ficoll blood 
mononuclear cells after 5 hours of in vitro activation. Cells were incubated with 
50 μg/ml LPS, 1.5 μg/ml PMA (Sigma-Aldrich, St. Louis, MO), and 3 μg/ml 
ionomycin (Sigma-Aldrich); with LPS, 10 μg/ml anti-CD40 (Bioceros BV, Utrecht, 
The Netherlands), and 10 μg/ml IL-4 (U-Cytech, Utrecht, The Netherlands); or 
with 10 μg/ml PAM3CSK4, anti-CD40, and IL-4. After 1 hour of incubation, 
10 μg/ml Golgi-stop (BD Biosciences) was added. Additional antibodies used 
for flow cytometry were IL-10-PE, TNF-α-PE-Cy7, CD19-HorV500 (all from 
BD Biosciences), IFN-γ-PE-Cy7, TGF-β-PE-Cy7 (both from BioLegend, San 
Diego, CA), IL-6-PE (eBioscience), and CD69-PE (Serotech, Kidlington, UK). 
Quantification of serum immunoglobulin levels
IgG, IgA, and IgM serum levels were measured with an 
immunoturbidimetric method (Hitachi Analyzer; Roche, Basel, 
Switzerland). IgG and IgA subclasses were determined using the 
immunonephelometric method (Sanquin, Amsterdam, The Netherlands).
Vaccination responses 
Responses to T cell-dependent influenza A/H1N1 (2007), A/H3N2 (2007) 
and B/Brisbane (Agriflu), and influenza A/H1N1 (2009) (Focetria; both 
from Novartis Pharma, Basel, Switzerland) vaccines were measured 
before and 4 weeks  after vaccination with a standard 
hemagglutination-inhibition (HI) assay (28). A 4-week 
postvaccination HI titer of at least 1:40 combined with a more 
than fourfold increase in titer was defined successful (29, 30). 
Specific IgG and IgA levels were determined before and 4 weeks after 
vaccination with T cell-independent Streptococcus pneumoniae 
(Pneumo23) and serum levels of Haemophilus influenzae type B antigens. 
Adequate pneumococcal response was defined as more than fourfold 
increase over baseline or postimmunization titer values of more than 0.35 μg/ml
for at least four of the six serotypes (28). H.  influenzae vaccination was 
considered effective with an antibody concentration greater than 1μg/ml (31). 
Amplification and sequence analysis of immunoglobulin heavy-chain  transcripts
IGA and IGG transcripts were amplified from B cells in thawed mononuclear 
cells of patients with sarcoidosis and control subjects, cloned into pGEM-T 
easy vector (Promega, Madison, WI), and sequenced on an ABIPRISM
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3130XL (Applied Biosystems, Carlsbad, CA) as described previously (24). 
Obtained sequences were analyzed with the IMGT 
database (http://imgt.cines.fr/) to assign V, D and J genes; to identify 
somatic mutations and to characterize the complementarily determining 
region (CDR)3 (32). IgA and IgG subclasses were determined using the 
immunoglobulin heavy chain (IGH) reference sequence (NG_001019).
Statistics
Statistical analyses were performed using the Mann-Whitney test (SPSS 
v18.0). A P value less than 0.05 was considered statistically significant.
Results
Patients
In this study, 32 patients with biopsy-confirmed sarcoidosis (13 male and 19 
female) were included (mean age, 48 yr; range, 19-78 yr). Patients 1 through 
28 had not received immunosuppressive drugs for at least 6 months, and 
patients 29 through 32 received infliximab (Table 1). The average duration of 
disease at study inclusion was 6.3 years (range, 1- 31 yr), and most patients had 
multiple organ involvement. Mean values of serum levels of angiotensin converting 
enzyme, B cells, CD4+ T cells, CD8+ T cells, and natural killer cells were within 
normal ranges for patients not receiving immunosuppressive drugs (Table 1).
Large numbers of B cells surround granulomas in patients with sarcoidosis
Haematoxylin and eosin-stained tissue biopsies of the granulomas 
did not show signs of necrosis. To study the presence of B cells in 
granulomas and their position in relation to T cells, several tissue biopsies were 
studied with immunohistochemistry. T cells that stained positive for CD3, CD4, 
CD5 and CD8 were easily detectable in all samples and were mainly located 
inside the granulomas (Figure 1). B cells were observed in all tissues. However, 
these were located in different areas as compared with T cells. B cells were 
predominantly located in the vicinity of the granulomas and in 5 of the 17 
patients also inside the granulomas (Figure 1). These concerned mostly 
CD20+, CD79a+, and PAX5+ B lymphocytes, but also CD138+ plasma cells 
were found (Figure 1). The latter mostly produced IgA, followed by IgG and 
IgM (Figure 1). These patterns were comparable between the various tissues, 
including skin samples in which IgA plasma cells are not normally found (33). 
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Thus, the consistent presence of large numbers of B cells surrounding granulomas
is suggestive of their involvement in the pathogenesis of sarcoidosis.
Abnormal naive and memory B cell subset distributions in blood of sarcoidosis 
patients
To study the peripheral B-cell compartment in more detail, we performed
extensive immunophenotyping of blood B cells in 28 patients and 28
age-matched healthy control subjects. There was no significant difference
of total B-cell numbers (CD19+) between these groups. 
Figure 1. Large perigranuloma B cell infiltrates in affected tissue of 
patients with sarcoidosis.
Representative images of staining with hematoxylin and eosin (H&E), CD3, CD20, CD138, 
and IgA of a skin and a lymph node of the neck biopsy from patients with sarcoidosis. 
Representative pictures of skin and lymph node of patients with sarcoidosis are shown.
Within the CD19+ B-cell compartment, we distinguished two naive populations,
CD21low anergic B cells, six memory B-cell subsets, and plasma cells (Figure 2)
(23). CD24hiCD38hi transitional and naïve mature B cells were similar
in patients compared with healty control subjects (Figure 3A). Of the 
six memory B-cells subsets, natural effector B cells, CD27+IgM+, 
CD27+IgG+, and CD27+IgA+ memory B cells were significantly reduced
compared with healthy control subjects (all P < 0.0001) (Figure 3A). 
Although CD27-IgG+ memory B cells were similar, T cell-independently
derived CD27-IgA+ B cells were significantly increased in patients
with sarcoidosis (P = 0.002) ( Figure 3A). Independent of disease duration, the
fraction of CD21lowCD38low anergic B cells and circulating plasma cells was
reduced compared with healthy control subjects (Figure 3C and 3D) (8).
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Together, these data indicated that despite normal to high output of naive
B cells from bone marrow, patients do not show increased anergy
but appear impaired in generation or maintenance of normal numbers
of most subsets of circulating memory B cells and plasma cells.
Figure 2. Blood B cell subset analysis with multicolor flow cytometry.
(A) Schematic representation of B cell maturation indicating the subsets that can be detected in peripheral
blood. Transitional B cells are recent bone marrow emigrants and will develop into naïve mature
B cells. CD27-IgA+ and natural effector B cells can be derived independently from T cell help. 
CD27+IgM+ and CD27-IgG+ memory B cells resembled those of primary germinal center cells, whereas
CD27-IgG+ and CD27+IgA+ memory B cells has increased proliferation and somatic hypermutation
levels suggestive of further maturation in consecutive germinal center response (22). Representative
dot plots of flow cytometric analysis of a healthy control subject (B) and a patient with sarcoidosis
(C) are shown. All B cell subsets are determined within the CD19+ lymphogate.
To determine whether distinct tissue involvement affected the B-cell compartment
differently, blood B-cell subset numbers were compared between patients 
with (n = 21) and without pulmonary involvement (n = 7) (Figure 3B).
Whereas transitional B cells only were increased in patients with pulmonary
involvement,   the patterns of circulating CD21low CD38low B cells, memory B-cell
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subsets and plasma cells were similar between the two groups. Thus, 
most effects on the peripheral B-cell compartment are most likely
unrelated to pulmonary involvement in patients with sarcoidosis.
Figure 3. Blood B cell subsets are affected in sarcoidosis.
(A) Transitional and naïve mature B cells were normally present in patients with sarcoidosis. Significantly
reduced numbers of natural effector B cells, CD27+IgM+, CD27+IgG+, and CD27+IgA+ memory B 
cells and plasma cells were found in patients with sarcoidosis as compared with healthy control subjects,
whereas CD27-IgG+ were normally present and CD27-IgA+ B cells were significantly increased. (B)
All abnormalities found in A were similar between pulmonary and without pulmonary sarcoidosis 
(P > 0.17). (C) CD21lowCD38low anergic B cells of patients were significantly reduced as compared
with healthy control subjects. (D) No effect was seen of disease duration of sarcoidosis on the frequencies
of CD21lowCD38low anergic B cells. Values are expressed as cell counts (cells/μl) ± SEM. Statistical
analysis was performed with the Mann-Whitney test. *P <0.05. **P <0.01. **** P <0.0001.
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Normal total serum immunoglobulin levels and antigen-specificimmunoglobulin
responses in patients with sarcoidosis. 
The impaired humoral immune response in patients with CVID is related to 
reduced numbers of circulating memory B cells (18). Comparably 
low numbers of memory B cells in the studied patients prompted 
us to analyze total serum immunoglobulin levels and immunoglobulin 
responses after vaccinations with T cell-dependent and T cell-independent 
antigens. In contrast to patients with CVID, normal levels
of total serum IgG, IgA and IgM levels, as well as IgG and IgA subclass levels 
were observed in all tested patients (Table 2). Thus, terminal differentiation 
of B cells into immunoglobulin-producing plasma cells appeared unaffected
in patients. The vaccination response of all patients for T cell-dependent seasonal
flu (Agriflu 2009-2010) and Mexican flu (Focetria) antigens were within 
the normal range. In addition, in all patients but one, normal responses to 
T cell-independent Streptococcus pneumoniae and H.  influenzae type B antigens
were generated. One patient (patient 16; Table 1) did not respond adequately
to S. pneumonia but responded normally to H. influenza, and the B-cell subset
distribution of this patient was comparable with the whole group. 
Thus, patients with sarcoidosis are capable of mounting normal immunoglobulin
responses with or without assistance of T cells. 
Increased molecular signs of antibody maturation in patients with sarcoidosis
Despite the reduced numbers of circulating memory B cells, immunoglobulin
responses were normal in patients with sarcoidosis. To determine whether this
applies to the molecular levels, we studied somatic hypermutations (SHMs)
and IgA and IgG subclass use in sequenced IGH transcripts of B cells from 
our patients and three  healthy control subjects. Transcripts of all four patients
showed increased signs of antigen maturation, with high frequencies of
SHMs (Figure 4A and 4B) and accumulation of replacement mutations
in CDRs compared with healthy control subjects (Figure 4C and 4D). 
 To study antibody maturation in more detail, we determined the IgA
and IgG subclasses of the amplified transcripts (Figure 5B). IgA transcripts
showed similar distributions between patients with sarcoidosis and control
subjects with slightly more IgA1 usage than IgA2. Despite this, SHM levels
of IgA1 and IgA2 transcripts were increased in patients with sarcoidosis
as compared with healthy control subjects (Figure 5C).
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Table 2. Immunoglobulin levels and vaccination responses.
Before Vaccination 
Mean (Range) 
After Vaccination*-
Mean (Range)
Control 
Values
Serum immunoglobulin levels (n = 11)
Total IgM, g/L 1.1 (0.6-2.0) - 0.5-2.3
Total IgA, g/L 2.7 (1.5-3.7) - 0.8-3.9
      Total IgA1, g/L 1.9 (1.0-2.4) - 0.6-2.4
      Total IgA2, g/L 0.5 (0.2-0.6) - 0.1-0.6
Total IgG, g/L 12 (7.0-15.7) - 7.0-16.0
      Total IgG1, g/L 9.1 (5.3-11.3) - 4.9-11.4
      Total IgG2, g/L 2.9 (1.5-6.0) - 1.5-6.4
      Total IgG3, g/L 0.6 (0.2-1.1) - 0.2-1.1
      Total IgG4, g/L 0.9 (0.4-1.4) - 0.1-1.4
Vaccine 
Influenza A/H1N1 (2007) (n = 11) 88 (5-400) 371 (80-1280) -
Influenza A/H3N2 (2007) (n = 11) 50 (5-300) 375 (20-1760) -
Influenza B/Brisbane (2008) (n = 11) 28 (5-150) 347 (20-1280) -
Influenza A/H1N1 (2009) (n = 8) 52 (5-130) 432 (195-960) -
 Streptococcus pneumoniae IgG (n = 12)
      Serotype 1, μg/ml 1.1 (0.10-5.24) 2.2 (0.1-6.32) >0.35
      Serotype 3, μg/ml 0.4 (0.11-8.50) 2.4 (0.25-8.50) >0.35
      Serotype 4, μg/ml 0.3 (0.10-0.42) 1.9 (0.10-4.07) >0.35
      Serotype 5, μg/ml 1.1 (0.10-4.31) 2.6 (0.10-8.63) >0.35
      Serotype 9, μg/ml 0.7 (0.10-1.94) 2.6 (0.13-7.77) >0.35
      Serotype 23, μg/ml 0.4 (0.10-1.36) 2.4 (0.10-8.10) >0.35
Streptococcus pneumonia IgA (n = 10)
      Serotype 1, μg/ml 0.17 (0.06-0.66) 1.31 (0.63-1.42) >0.35
      Serotype 3, μg/ml 0.75 (0.00-1.75) 1.99 (0.87-4.30) >0.35
      Serotype 4, μg/ml 0.08 (0.00-0.18) 1.10 (0.34-1.18) >0.35
      Serotype 5, μg/ml 0.12 (0.04-0.20) 0.76 (0.35-1.24) >0.35
      Serotype 9, μg/ml 0.09 (0.00-0.18) 1.15 (0.43-1.70) >0.35
      Serotype 23, μg/ml 0.11 (0.00-0.38) 0.50 (0.06-1.29) >0.35
Haemophilus influenza type B (n = 12), μg/ml 1.5 (0.3-7.1) 44.0 (4.2-35.0) >1.0
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Figure 4. Extensive signs of antigen maturatation in IgG and IgA 
transcripts of sarcoidosis patients. 
(A and B) Transcripts of four representative patients were compared with three control subjects. All four 
patients showed high frequencies of somatic hypermutation (SHM) (n represents the total number of 
transcripts). (C and D) Similar accumulation of replacement mutations in CDR1 and CDR2 regions between 
patients with sarcoidosis and age-matched healthy control subjects. IGHV = immunoglobulin heavy chain 
variable.
IgG transcripts showed equal use of IgM-proximal IgG1 and IgG3 (58%) and 
IgM-distal IgG2 and IgG4 (42%) in patients with sarcoidosis and healthy control 
subjects (Figure 5B). IgG1 and IgG2 transcripts of patients with sarcoidosis showed 
increased levels of SHM, comparable to the IgA transcripts. Thus, although IgA 
class switching appears unaffected, increased levels of both SHMs and increased 
immunoglobulin-class switching to downstream IgG regions suggest that B-cell 
memory in patients with sarcoidosis is generated in prolonged or additional 
immune responses. Therefore, despite reduced numbers of circulating memory 
B cells and plasma cells, patients with sarcoidosis are fully capable of generating 
functional humoral immunity with molecular signs of antigen maturation.
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Figure 5. Increased Ig class switching to downstream IgG subclasses in 
patients with sarcoidosis.
(A) Schematic representation of the constant region of the human immunoglobulin heavy-chain (IGH) locus. 
(B) Distribution of IgA and IgG receptor subclass use in IGH rearrangements of class-switched memory 
B cell subsets is shown. IgA transcripts showed equal IgA1 and IgA2 usage in patients with sarcoidosis as 
compared to control subjects. IgG transcripts from control subjects showed a trend of dominant use of IgG1 
and IgG3 (58%) over IgG2 and IgG4 as compared with SP (42% IgG1 and IgG3). Total number of analyzed
sequences is indicated in the center of each plot. (C) Somatic hypermutation levels of IgA1, IgA2, IgG1 
and IgG2 transcripts were increased in patients with sarcoidosis as compared with control subjects. 
Statistical analysis was performed with the Mann-Whitney test, * P < 0.05, ** P < 0.01, *** P < 0.001.
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Figure 6. Sarcoid B cells showed elevated expression of CD19, CD21 and 
decreased expression of CD45 with normal CXRC3 levels.
(A) CD19, CD21, and CD45 expression in a representative patient (red), a healthy control (blue), 
and negative control subject (gray). Significant lower expression was found in a patient with 
sarcoidosis of CD19 and CD20. CD45 expression was slightly elevated in patients with sarcoidosis. 
(B) CXCR3 expression in a representative patient (red) and a healthy control subject (blue) showed
no difference in expression on transitional, natural effector, or CD27-IgA+ B cells.
Figure 7. Normalization of CD27-IgA+ memory B cells in patients with 
sarcoidosis treated with a TNF-α blocker.
CD27-IgA+ memory B cells were compared between patients with sarcoidosis
without treatment and treatment with infliximab (a TNF-α blocker). The CD27-IgA+ memory
B cell population normalized in patients who were treated with infliximab.
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No production of TNF-α and increased levels of IFN-γ by stimulated B cells
To determine if the distinguished B-cell differentiation in patients with sarcoidosis 
was directly involved in local inflammatory processes in sarcoidosis, functional 
analysis in five patients (patients 13, 15, 18, 19, and 22) (Table 1) was performed. 
Sarcoid B cells showed decreased expression of CD19 (mean fluorescence intensity
[MFI], 2,335) and CD21 (MFI 2,561) and elevated expression of CD45 (MFI 1,300) 
as compared with healty control subjects (Figure 6A). CXRC3 levels of patients 
with sarcoidosis and healthy control subjects were similar in all B cells (Figure 6B). 
B cells of patients with sarcoidosis were stimulated in three different cultures 
(culture 1: LPS, PMA, ionomycin; culture 2: LPS, CD40L, IL-4; and culture 3: 
PAM3CSK4, CD40L, IL-4). After stimulation, no significant difference between 
patients with sarcoidosis and healthy control subjects in the levels of 
expression of TNF-α, TGF-β, IFN-γ, IL-6, and IL-10 was found.
Population of CD27-IgA+ memory B cells normalized in patients currently 
treated with TNF-α blockers
To study the effect of TNF-α blockers on B cells, we determined the B-cell 
differentiation in four patients (patients 29-32) (Table 1) who were currently 
treated with a TNF-α blocker (i.e., infliximab) and compared them with healthy 
control subjects. All B-cell subsets were similar except for CD27-IgA+ memory 
B cells. In patients with sarcoidosis, this B-cell population was significantly 
increased as compared with healthy control subjects. In patients currently 
treated with TNF-α blockers, this population normalized (P = 0.045) (Figure 7). 
Thus, the elevated population of CD27-IgA+ memory B cells in patients 
with sarcoidosis normalizes after treatment with a TNF-α blocker. 
Discussion 
In this study, we analyzed distribution patterns and cellular and molecular 
characteristics of B cells of patients with sarcoidosis. The observations 
suggest skewing of memory B cells toward granulomatous tissue. This and 
our observation of increased circulating transitional B cells and normal 
immunoglobulin responses to vaccination but increased molecular 
signs of antibody maturation indicates an overactive B-cell response 
that might play a role in disease pathophysiology of sarcoidosis.
  The presence of B cells in or close to granulomas of patients with 
sarcoidosis may be of clinical significance. To our knowledge, the only report
of B cells in sarcoid granulomas was published in the early 1990s and was 
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restricted to lung and lymph node biopsies (12). Despite the reported high 
numbers of B cells around granulomas, no studies have been reported since. 
Hypergammaglobulinemia can be found in patients with sarcoidosis (10). 
Thus, it is conceivable that immunohistochemical studies were focused on 
staining against immunoglobulin secreting plasma cells and not 
against B cells (10). Our findings revealed, apart from low plasma cell presentation, 
large numbers of B cells in granulomatous tissue of various affected organs, 
suggesting that these are disease related and not organ dependent.
  Detailed analysis of naive B cells in blood revealed increased numbers of 
transitional B cells in line with a previous study (34). Because transitional B cells 
are recent bone marrow emigrants, B-cell output from bone marrow does not 
appear impaired in patients with sarcoidosis. Decreased frequencies of anergic 
CD21lowCD38low B cells were found in our study. The reduction of 
CD21lowCD38low B cells contradicts published work by Lee and colleagues, who 
described low levels of CD21 expression on B cells and increased anergy in 
patients with chronic sarcoidosis with disease duration of more than six years (8). 
Of the 28 studied patients, only seven have been diagnosed more than six years 
before. However, no increased anergy was observed in these patients. Apparently, 
our patients do not display increased anergy in their B-cell compartment. 
  In line with previous observations, we found reduced levels of 
CD19 and CD21 and elevated CD45 levels on B cells of our patients with 
sarcoidosis (8). CD19 and CD20 are positive regulators of B-cell receptor 
signal transduction (35). In fact, human CD19 and CD20 deficiencies result 
in a higher threshold for activation and thus hyporesponsiveness to 
transmembrane stimulation (36, 37). Reduced CD19 or CD20 expression 
can result in reduced responsiveness of these lymphocytes. 
  The blood memory B-cell compartment is clearly affected in 
patients with sarcoidosis, with significantly reduced numbers of natural 
effector B cells and T cell-dependent CD27+IgM+, CD27+IgG+, and 
CD27+IgA+ memory B-cell subsets. An overall decrease of CD27+ memory 
B cells has been reported recently in severe chronic sarcoidosis (8, 34). 
However, our more detailed analysis reveals that this is mostly due to a 
decrease of mainly T cell-dependent B-cell memory in sarcoidosis.
  In contrast to the CD27+ memory B cells, T cell-independent CD27-
IgA+ memory B cells are increased in the studied patients. Furthermore, 
plasma cells in granulomatous tissue produce mostly IgA. These findings 
are especially interesting because IgA-producing plasma cells produce 
TNF-α, one of the key cytokines in the pathogenesis of sarcoidosis (7, 38). 
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However, after stimulation of CD27-IgA+ memory B cells with LPS+PMA, 
CD40L, or PAM3CSK4, we did not observe TNF-α expression in these cells. 
Because these cells did not produce cytokines after a 5-hour stimulation with 
these broad stimuli, we did not pursue stimulation experiments with specific s
arcoid antigens. Infiliximab is a TNF-α blocker and is used in the treatment 
of sarcoidosis (3). We found that treatment with a TNF-α blockers normalizes 
the population of CD27-IgA+ memory B cells. Thus, circulating numbers 
of CD27-IgA+ memory B cells could be a marker of sarcoidosis activity. 
  Despite the strongly reduced number of memory B cells in blood, 
patiens with sarcoidosis show only slightly reduced numbers of circulating 
plasma cells, normal serum immunoglobulin levels, and normal responses 
to vaccinations. This is in line with previous studies demonstrating 
normal vaccination responses to influenza vaccinations and the clinical 
observation that untreated patients display no increased risk for 
infections (39, 40). Therefore, it is unlikely that the decreased numbers of 
memory B cells are the result of impaired B-cell responses. 
  Detailed molecular analysis of IgA and IgG memory B cells in this study 
demonstrate increased SHM levels and increased immunoglobulin class switching 
to downstream IgG subclasses in patients with sarcoidosis compared with 
control subjects. These molecular patterns suggest that memory B cells in 
sarcoidosis have been exposed to prolonged B-cell stimulation or consecutive 
responses (19, 41, 42). Thus, it is unlikely that patients have defects in the 
generation of B-cell memory but rather have involvement and migration of 
antigen-experienced B cells towards granulomatous tissue. Further evidence 
for chronic B-cell stimulation is the increased risk for patients to develop a 
malignant lymphoma (sarcoidosis-lymphoma syndrome) (41, 43, 44). These 
lymphomas are predominantly of B-cell origin. It is thought that these B cells 
undergo malignant transformation after chronic stimulation (45). 
  The abnormalities in the peripheral B-cell compartment in sarcoidosis 
with increased numbers of transitional B cells and decreased memory B-cell 
numbers is similar to patients with granulomatous CVID (18, 46-48). However, 
in contrast to patients with CVID, vaccination responses, circulating plasma 
cell numbers, and serum immunoglobulin levels and degrees of antibody 
maturation were not severely affected in patients with sarcoidosis. In 
contrast to patients with CVID who do have circulating B cells, granuloma 
formation has not been reported in patients with complete B-cell 
deficiency (e.g., with X-linked agammaglobulinemia) (49). Additionally, in 
animal models of T-cell-deficient mice, it has been shown that B cells are
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crucial for noninfectious granuloma formation (50). Thus B cells 
appear to be essential for granuloma formation in antibody-deficient 
patients and in patients with sarcoidosis. 
  In conclusion, our extensive analysis of B cells in patients with sarcoidosis 
demonstrates significant B-cell infiltrates in granulomatous tissue, whereas 
blood memory B-cell compartment is reduced in size (despite normal 
immunoglobulin responses) and skewed to locally produced CD27-IgA+ 
B cells. These data are indicative of direct involvement of B cells in local 
inflammatory processes in granulomatous tissue of patients with sarcoidosis 
with CD27-IgA+ B cells as a potential marker for disease activity of sarcoidosis. 
Therefore, our study provides a rationale for a systematic study on B-cell 
ablative therapy (e.g., with rituximab) in patients with sarcoidosis.
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Abstract
Granulomatous disease occurs in 10-22% of the patients with common 
variable immunodefiency (CVID). The presence of granulomas in 
CVID is associated with a worse prognosis and increased prevalence of 
lymphoproliferative disorders. This study was performed to investigate 
the frequency and to identify markers for granulomatous CVID. 
Patients and methods
In this study we present the data of 37 CVID patients prospectively and randomly 
analyzed with an OctreoScan to screen for granulomatous lesions. Flow cytometric 
analyses involved peripheral blood lymphocytes and B cell subsets. Serum 
levels of the granulomatous markers angiotensin converting enzyme 
(ACE) and soluble interleukin-2 receptor (sIL-2R) were measured.
Results
The OctreoScan was negative in 11 patients, 5 patients had one lesions and 
21 patients had more than one lesion. Most localizations were found in the 
lungs (73%), but salivary and inguinal glands lesions were common as well 
(respectively 12% and 19%). In 5 of the 26 patients with lesions it was 
histological proven to be granulomas. B cell subsets, T cell subsets and monocyte 
numbers do not differ significantly between non-granulomatous and 
granulomatous CVID. Serum levels of ACE were elevated in 8 of the 24 
patients. Of these 8 patients, 7 patients had granulomas. Contradictionary to 
ACE, no correlation was found between granulomatous CVID and sIL-2R. 
Conclusion
Our preliminary data suggest that based on OctreoScan the percentage of 
granulomatous disease in CVID is underestimated. Probably due to the 
fact that after diagnosing CVID no further research is performed to look 
if there are granulomas. 70% of the CVID patients in this study had lesions 
suspected for granulomas. Elevated levels of serum ACE may indicate 
granulomatous disease in CVID. Prospective studies are warranted to 
investigate the role of total body scintigraphy in patients with CVID.
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Introduction
Common variable immunodefiency (CVID) is characterized by hypogamma-
globulinaemia, recurrent infections and an impaired B cell compartment. A 
maturation arrest in the B cell development and/or disturbed B-T cell interaction 
results at the end in an antibody deficiency with poor vaccination responses (1). 
Granulomas can be found in a subgroup of patients with CVID. This subgroup 
is often regarded as having a “sarcoid-like syndrome” and are reported to have 
an impaired prognosis (2). In previous reports it has been estimated that 
in CVID, granulomatous disease occurs in 10-22% of the patients (3-5).
  Sarcoidosis is a multisystem disorder with a hallmark of non-caseating 
granulomas (2, 6, 7). Recently we reported abundant perigranuloma B cell 
infiltration including IgA producing plasma cell involvement in sarcoid 
granulomas (8). In contrast to patients with CVID, sarcoidosis patients 
have normal serum immunoglobulin levels and normal antigen-specific 
immunoglobulin responses (7). Sarcoid granulomas can produce serological 
markers such as angiotensin-converting enzyme (ACE) and soluble interleukin-2 
receptor (sIL-2R) (28, 29). ACE and sIL-2R are widely used in the 
assessment and follow-up of sarcoidosis (1, 5).
  Recognition of granulomatous CVID is of great clinical importance. The 
presence of granulomas in CVID is associated with a worse prognosis because of 
organ damage and increased prevalence of lymphoproliferative disorders (8). 
As a consequence, granulomatous CVID patients should be monitored at the 
outpatient clinic more intensively than CVID patients without granulomas. 
  Previously, the visualization of granuloma localizations was reported in 
patients with sarcoidosis with scintigraphy using a radiolabeled somatostatin 
analog (OctreoScan) (10, 11). This analog binds to granulomas but is not specific 
for granulomas only. Somatostatin receptors (Sst) are expressed in specific 
inflammation like granulomas but are also expressed by Sst baring tumors. 
Imaging techniques such as OctreoScan are a sensitive technique to visualize 
granuloma localizations and to define the extent of disease (9). 
  It is not exactly known how many CVID patients have granulomatous 
involvement. In this study we retrospectively evaluated CVID patients for 
granulomas by OctreoScan. The extent of disease in patients with granulomatous 
CVID on OctreoScan was compared with the disease pattern of sarcoidosis. 
Granuloma biomarkers ACE and sIL-2R and peripheral B-T and monocytes 
numbers were related in patients with non-granulomatous CVID with 
presumed granulomatous CVID based positive OctreoScans. 
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Patients and methods
Patients
In this prospective study we analyzed 37 random CVID patients with OcteoScan 
from January 1997 to December 2012. We compared the pattern of suspected 
and confirmed granulomatous CVID patients with 175 patients with 
sarcoidosis who underwent OctreoScan in the same time span.
For diagnostic purposes, we performed tissue biopsies in four patients with 
granulomatous CVID in order to rule out malignancy. We assume that OctreoScan 
positive sites in CVID patients resemble granulomatous inflammation, tissue 
biopsies for conformation are not permitted for ethical reasons. 
In vivo scintigraphy; OctreoScan
The used scintigraphy technique has been described extensively elsewhere (10-12). 
Summarizing; In-111 pentetreotide is a [In-111 DTPA-D-Phe-] conjugate of 
octreotide, a long-acting somatostatin analog (OctreoScan®). The recommended 
administered activity is 222 MBq (6 mCi) in adults. The amount of pentetreotide 
injected is 10-20 mcg; that dose is not expected to have a clinically significant 
pharmacologic effect. Images are acquired at 4 and 24 hour and on indication 
or 48 hour post injection. The 48 hour images may be needed when there is 
significant bowel activity at 24 hour, which may potentially obscure lesions. 
We studied and compared retrospectively the extent of 
inflammatory sites in both patient groups. 
Serum analysis
Serum levels of ACE were determined in 24 patients. Serum ACE levels was 
measured using the Bühlmann ACE kinetic test (Siemens Medical Solutions 
Diagnostics, Breda, The Netherlands). An enzyme-linked immunosorbent 
assay (ELISA, Diaclone, Besançon, France) was used to detect serum levels 
of sIL-2R in 28 patients. Serum ACE levels > 68 U/l and serum sIL-2R 
levels > 2500 pg/ml (reference values) was considered increased.
Flow cytometric analysis of peripheral blood lymphocytes and B cell subsets
Diagnostic work-up and detailed studies of blood were carried out with 
informed consent following the Declaration of Helsinki and according to 
the guidelines of the Medical Ethics Committee of Erasmus MC.
Absolute counts of blood CD4+ and CD8+ T cells as well as CD16/56+ NK 
cells and CD19+ B cells were obtained with a diagnostic lyse-no-wash 
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protocol for 19 patients with granulomatous CVID. Furthermore, 8-color 
flow cytometric immunophenotyping was performed to detect transitional, 
naive mature and six memory B cell subsets using the following monoclonal 
antibodies: CD24-PB (SN3; ExBio), CD45-PO (HI30; Invitrogen), IgM-FITC, 
IgD-PE, IgG-PE, IgA-PE (all goat polyclonal from SBA), CD19-
PerCP-Cy5.5 (SJ25C1), CD21-PE-Cy7 (B-ly4), CD27-APC (L128), CD38-APC-H7 
(HB7), IgD-biotin (IA6-2; all from BD Biosciences). Biotinylated antibodies 
were detected with Streptavidin PE-Cy7 (eBioscience).
Figure 1. Examples of OctreoScan in CVID patients.
 
A, negative OctreoScan; B, uptake in the lungs and axillae; C, uptake in joints of the hand; D, uptake in the 
knees; E, cutaneous uptake; F, uptake in the nose; G, uptake in shoulder; H, uptake in ankles.
Results
Scintigraphy was negative in 11 of the 37 CVID patients (30%), 5 patients 
(14%) had one lesion suspected for granulomas and 21 patients (57%) had more 
than one lesion on OctreoScan. Figure 1 shows 2 examples of OctreoScan uptake 
in CVID patients. Similar to Resnick et al, most localizations of granulomatous 
CVID were found in the lungs (73%), but localizations in salivary and 
inguinal glands were common as well (respectively 12% and 19%) (13). In 4 
of the 26 patients with uptake on OctreoScan a biopsy was taken for 
differential diagnostic purposes, which revealed non-necrotizing granulomas. 
We compared granuloma sites as detected with the OctreoScan in granulomatous 
CVID and a group of 175 sarcoidosis patients. Both groups showed almost 
a similar pattern. These results are summarized in Table 1. 
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Table 1. Lesions on OctreoScan in 37 patients with CVID and a group of 
175  sarcoidosis patients in percentages (%).
Involved sites CVID Sarcoidosis
Thoracic 73 94
   Hilar 31 71
   Mediastinal 19 47
   Lung parenchyma 38 38
Salivary glands 12 33
Inguinal 19 18
Skin 8 6
Serum ACE levels were measured in 24 CVID patients and in 8/24 these were 
elevated. Of these 8, 7 (88%), showed uptake on OctreoScan. In 24 of the 28 patients 
serum levels of sIL-2R were elevated. In contrast to ACE, no correlation was found 
between granulomatous CVID and sIL-2R. Mean serum sIL-2R level of patients 
with uptake on OctreoScan was 5574 pg/ml (range 5507 pg/ml - 19891 pg/ml) 
versus 8919 pg/ml (range 2998 pg/ml - 29793 pg/ml) of patients with no uptake. 
  In order to study if peripheral blood cell counts reflect the presence of 
granulomas we compared the results with the data of our CVID cohort. In 19 
patients with SRS uptake the peripheral blood B- and T cell subsets were determined. 
Mononuclear cell numbers were extracted from leucocyte differential. The B cell 
subsets, T cell subsets and monocyte numbers do not differ significantly (Table 2). 
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Table 2. Peripheral blood lymphocyte levels of non-granulomatous and 
granulomatous CVID patients.
Non-granulomatous CVID 
(n= 58)
Granulomatous CVID 
(n= 19)
P-value
T cells/μL 120 1610 0.06
Natural killers cells/μL 20 10 0.65
B cells/μL 30 10 0.57
Transitional B cells 12.9 6.7 0.79
Naive mature B cells 211.9 84.1 0.07
Natural effector B cells 65.6 25.4 0.29
CD27+IgM+ 2.1 2.0 0.41
CD27+IgG+ 7.6 2.7 0.45
CD27-IgG+ 6.7 2.7 0.14
CD27+IgA+ 4.4 2.2 0.24
CD27-IgA+ 6.0 3.6 0.56
Plasma cells 0.2 0.2 0.91
Statistical analyses were performed using the Mann-Whitney test (SPSS v18.0).
Discussion
In this study, we analyzed the presence of granulomas in CVID patients. The 
results suggests that the frequency of granulomas is underestimated and that 
elevated levels of serum ACE may indicate granulomatous disease in CVID.
  In the literature only a few reports on granulomatous CVID exist and 
reported frequency of granulomas is low (based on autopsy records) (4, 5). The 
results of our study suggest that, granulomatous lesions in CVID are more prevalent 
than expected from previous data. However, we have to take in regard that in 
only four out of 26 patients the lesions on scintigraphy were confirmed by 
histopathological examination. No other material was available for 
histopathological examination. OctreoScan has been performed for diagnostic 
work-up in patients with granulomatous disease in order to determine the affected 
organs. This technique is used to determine the extent of disease, for directed 
radiological examination and to explore a biopsy site (12, 30). A withdrawal of this 
technique is aspecific accumulation of radioactivity in the liver and specific 
visualization of the spleen which makes granuloma detection unreliable in these 
frequently affected organs. Since randomly biopsies were made, the presented 
data suggest an underestimation of granulomatous lesions in CVID patients. 
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The choice of scintigraphy may be a matter of debate. On 18F-FDG PET 
granulomatous lesions can be visualized as well, however as with OctreoScan, 
histopathological confirmation is sparse. No data are reported concerning the 
sensitivity between OctreoScan and 18F-FDG PET. In a preliminary study in 
our hospital 7 sarcoidosis patients underwent an OctreoScan and 18F-FDG PET. 
OctreoScan reveals more inflammatory localizations (data not shown). 
  We compared the affected organs between granulomatous 
CVID and sarcoidosis patients, showing no differences in affected 
sites. In previous studies and similar to our study, it has been reported 
that lungs were affected more frequently (4, 5).
  Analysis of lymphocyte subsets in granulomatous CVID and 
non-granulomatous CVID did not reach significant differences suggesting that 
peripheral T-B lymphocytes and monocytes do not predict granuloma formation. 
  ACE and sIL-2R are widely used in the assessment of sarcoidosis (16). 
Increased serum levels of ACE are reported in 50% of the patients with sarcoidosis 
and is supposed to reflect the total granuloma mass (13, 14). This study showed 
elevated levels of serum ACE in 8 of the 24 CVID patients. Of the 8 patients, 7 
patients had granulomas (88%, i.e. positive uptake on scintigraphy). 
Contradictionary to ACE, no correlation was found between granulomatous 
CVID and sIL-2R. Therefore elevated levels of serum ACE in 
CVID patients are suggestive for granulomas and could be a 
potential marker for granulomas in CVID patients. 
  Granulomatous lesions in CVID have a significant negative 
effect on survival, thus early detection is important in the management 
of the disease process (17). In summary the presented data suggest 
an underestimation of granulomas in CVID and implies to search for 
tools to improve predictive information on this subject. The 
consequences of our data warrants a prospective trial in which scintigraphy 
will be performed at diagnosis and certain time points with a long-term 
follow up in order to evaluate morbidity and mortality.
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Abstract
It remains unclear whether atopy is associated with the occurrence of 
sarcoidosis or affects its severity. The purpose of this study was to compare the 
lifetime prevalence of atopic eczema, asthma, and hay fever in sarcoidosis 
patients with controls and to assess whether atopy influences the severity of 
sarcoidosis. 
Methods
The prevalence of atopic disorders assessed with a validated postal 
questionnaire in sarcoidosis patients with pulmonary, uveitis, and cutaneous 
sarcoidosis was compared with that of their domestic partners in a case-control 
study. The serological parameters, the pulmonary function tests, and the 
high-resolution computed tomography (HRCT) scans of atopic and nonatopic 
sarcoidosis patients were compared in a nested cohort. Multivariate logistic 
regression models were used to calculated the odd ratios (ORs) and the 95% 
confidence intervals (CIs). 
Results
Two hundred twente-five sarcoidosis patients and 177 controls were included. 
The prevalences of atopic eczema, asthma, and hay fever were comparable 
between patients and controls (12.4% versus 12.4%, 5.3% versus 5.6%, and 
16.9% versus 15.8%, respectively). After adjusting for gender and ethnicity, 
those with sarcoidosis and a history of atopic eczema were significantly less 
likely to have uveitis (OR, 0.30; 95% CI, 0.13-0.71). Within the sarcoidosis 
cohort, the distributions of serological markers, the lung function tests, and 
the HRCT scans were similar between atopic and nonatopic patients. Atopy 
is not associated with the occurrence of sarcoidosis, but atopic eczema may 
decrease the likelihood of eye involvement. 
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Background
Sarcoidosis is a systemic granulomatous disease of variable clinical 
presentation and course. Over 90% of the patients have thoracic involvement, 
but the skin, the eyes and other organs may also be affected (1). The 
annual incidence is estimated at 20 per 100,000 (2). It is thought to 
be mainly T-helper type 1 (Th-1) driven, but the exact etiology is 
unknown. Predisposing factors for sarcoidosis are black race, female sex, 
age between 20 and 40 years and a family history of sarcoidosis (3). An 
uncontrolled study in 41 Turkish sarcoidosis patients revealed a lower 
prevalence of asthma and positive skin prick tests as compared with the 
expected rate based on national data (4). 
  Two studies by Hattori et al, reported lower total serum 
immunoglobulin E (IgE) in sarcoidosis patients and fewer parenchymal 
lung lesions in chest X-rays in atopic sarcoidosis patients (19% vs. 37%; 
p=0.018) (5, 6). However, no evidence of a lower prevalence of atopic 
asthma was found in a cross-sectional survey among 136 sarcoidosis 
patients (7). Therefore, it remains unclear whether the prevalence of 
atopic disorders  is decreased in sarcoidosis patients and whether atopy
affects the severity of sarcoidosis. In this case-control study, the association 
between atopic disorders, sarcoidosis and detailed sarcoidosis 
characteristics in the largest cohort to date was investigated. 
Patients and methods
Study population
We approached by 371 consecutive patients with sarcoidosis diagnosed between 
2000 and 2012 at the Clinical Immunology outpatient clinic at the Erasmus 
Medical Center. Our center is a tertiary referral center with expertise in 
sarcoidal uveitis and cutaneous sarcoidosis. Patients’ medical records were available 
to the study team. The spouses/partners of the contacted patients were asked to 
act as controls. Participants were considered to be of Dutch ancestry if both 
of their parents were born in the Netherlands. Caribbean and Suriname 
subjects were those in whom one of the parents was born either in Suriname 
or the Caribbean. This study was conducted in accordance with the Declaration 
of Helsinki and the medical ethical committee of the Erasmus Medical Center 
provided a waiver for this single-subject questionnaire-based study. 
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Patient-reported atopic features 
Patients were sent an invitation letter, the questionnaire and a prepaid 
return envelope. Non-responders were contacted a second time via 
mail. The definitions of the atopic features (i.e. atopic eczema, hay fever and 
asthma) were self-reported and based on items from the European 
Community Respiratory Health Survey and International  Study of Asthma
and Allergies in Children protocol (8, 9). Subjects were considered to 
have had asthma if they answered the question “Have you ever been 
diagnosed with asthma by a doctor?” positively and if the answer to 
the question “How old were you when you were diagnosed with asthma?” 
was younger than 25 years. The criteria for the diagnosis of atopic 
dermatitis were: atopic dermatitis diagnosed by a physician, before the 
age of 25 and a duration of more than 1 year.  For diagnosis of hay fever 
patients had to answer the next question affirmatively; “Have you ever 
had hay fever before the age of 25 years?”. The age of 25 years was used 
as cut-off in order to increase the specificity as atopic disorders mainly 
have their onset during childhood and adolescence. This prevents 
misclassification of other forms of eczema as atopic eczema and of 
chronic obstructive pulmonary disease as atopic asthma. Patients were 
also asked about the use of topical corticosteroids for their atopic 
dermatitis, inhalants for the asthma and nasal sprays or 
anti-histaminics for the hay fever. The presence of atopic features in 
the first degree relatives was also assessed through this questionnaire.
Sarcoidosis types, activity and severity
Sarcoidosis patients were further classified into non-exclusive three groups: 
pulmonary sarcoidosis, sarcoidal uveitis and cutaneous sarcoidosis. The 
diagnosis of sarcoidosis was established according to the guidelines of the 
American Thoracic Society/European Respiratory Society/World Association 
of Sarcoidosis and other Granulomatous Disorders statement on sarcoidosis 
(10). The diagnosis of (posterior or anterior) uveitis was made by certified 
immunologists and confirmed by ophthalmologic examination. 
The diagnosis of cutaneous sarcoidosis was confirmed by biopsy.
  To assess the disease activity and severity (i.e., organ involvement 
and serological markers)  radiological, serological and pulmonary function 
tests were performed on clinical indication. Serological tests included erythrocyte 
sedimentation rate, T-lymphocyte levels, serum ACE and serum calcium. 
All patients suspected of having sarcoidosis routinely undergo high 
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resolution computed tomography scanning at our center. Modified Scadding 
scoring system was applied to High resolution CT-scanning (HRCT) in order 
to assess pulmonary sarcoidosis (11). All HRCTs were graded according to 
the Scadding system by a certified radiologist (12). The Scadding scale: 0 re
presents a normal chest HRCT, stage 1: bilateral hilar lymphadenopathy, stage 2: 
stage 1+ pulmonary infiltrates, stage 3: there are pulmonary infiltrates 
without hilar lymphadenopathy and stage 4 shows pulmonary fibrosis.
  In pulmonary sarcoidosis, pulmonary functioning may be impaired even 
in the absence of radiological abnormalities. Transfer factor for carbon monoxide 
(TLCO) and total lung capacity (TLC) are characteristically affected but the forced 
vital capacity (FVC) and forced expiratory 1 second volume (FEV1) are also 
frequently decreased (13, 14). Pulmonary function tests were performed according 
to the local protocol at the Pulmonology Department. The values of the parameters 
were expressed as a percentage of the expected value corrected for ethnicity, 
sex, age and haemoglobin levels. The classic serological parameters of the disease 
activity are angiotensin-converting enzyme (ACE), calcium (CA) and T-cell 
numbers. These were performed at the time of diagnosis according to 
the protocol of the Medical Laboratory at the Erasmus Medical Center.
  Patients were also asked to report the name of their current 
medication for sarcoidosis. If no medication was currently used and 
patients declared so the sarcoidosis was considered resolved.
Statistics
For sample size calculations, we assumed a prevalence of 20% of atopic disorders 
in our control group, as previously found (15) and expected half of this proportion 
in sarcoidosis patients. A convenience sample of about 200 cases was deemed 
resonable. We compared the prevalence of atopic features between the patients 
and the controls. In the cohort of sarcoidosis patients we also investigated 
whether the presence of atopic features was related to specific organ involvement 
in sarcoidosis (i.e. pulmonary, uveitis and cutaneous sarcoidosis). 
  The Chi-squared test was used to test for statistical differences in 
proportions and Mann Whitney-U tests for non-parametric testing. Age, 
sex and ancestry were considered confounders in the relation between sarcoidosis 
and atopy. Multivariate logistic regression models were used to calculate 
adjusted odds ratios (OR) and 95% confidence intervals (95% CI). Variables 
with p<0.20 in the univariate analysis were included in multivariate 
models. Values of p<0.05 were considered significant. All data were 
analyzed using IBM SPSS version 19.0 (Chicago, Illinois, 2011).
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Results
Subject characteristics
Of the 371 patients, 225 (61%) replied to our mailing with 177 control partners. 
The median age was 50 years for patients and 52 for controls. The controls 
were significantly more often males (54% vs. 39% p=0.003) and of Dutch 
ancestry (79% vs. 69% p=0.022) as compared with patients (Table 1).
Table 1. Subject characteristics. 
Sarcoidosis Patients
n = 225
Controls 
 n = 177
 p Value
Median age, yr (IQR) 50 (41-61) 52 (40-63) 0.928
Male sex 88 (39%) 96 (54%) 0.003
Family history of atopy 127 (56%) 99 (56%) 0.918
Ancestry
     Dutch 152 (69%) 137 (79%) 0.022
     Caribbean and Suriname 43 (19%) 18 (10%) 0.013
     Other 30 (13%) 22 (13%) 0.796
Pulmonary sarcoidosis 166 (74%)
Scadding score*
     Stage 0 26 (16%)
Stage 1 45 (27%)
Stage 2 59 (36%)
 Stage 3 9 (5%)
Stage 4 18 (11%)
no HRCT 9 (5%)
Sarcoidosis uveitis 126 (60%) n/a
Cutaneous sarcoidosis 92(45%) n/a
Median duration of sarcoidosis, yr 5.0 (IQR, 2.0-10.0) n/a
*0, normal chest HRCT; 1, bilateral hilar lymphadenopathy; 2, stage 1+ pulmonary infiltrates; 
3, pulmonary infiltrates without hilar lymphadenopathy; 4, pulmonary fibrosis.
IQR; interquartile range; HRCT = high-resolution computed tomography; n/a = not applicable.
Almost twice as many patients were of Surinam or Caribbean descent 
as compared with their partners (19% vs. 10% p=0.013). 
  Pulmonary involvement was found in 166 (74%) and in 157(95%) 
of these patients HRCT-scanning was performed. Uveitis and cutaneous 
sarcoidosis were seen in 126 (60%) and 92 (45%) of patients respectively. 
Pathogenesis
61
Atopic features and sarcoidosis
Sarcoidosis patients with pulmonary sarcoidosis did not differ from their partners 
regarding frequency of self-reported diagnoses of asthma, hay fever or eczema 
(Table 2). Moreover, drug use for atopic disorders and proportions of positive 
family histories did not differ across patients and controls. The same was the 
case for patients with cutaneous sarcoidosis. Adjusting for the confounders 
did not alter these results. However, patients with sarcoidosis uveitis reported 
eczema less often than the controls (26% vs. 12%, p=0.045) (Table 2).
Table 2. Prevalence of self-reported atopic disorders and their medication 
use.
Sarcoidosis
n = 225
Controls
n = 77
p Value
Atopic eczema
     Ever 28 (12.4%) 22 (12.4%) 0.996
     Current topical corticosteroid use 39 (18.6%) 21 (12.0%) 0.124
     Family history 70 (30.1%) 50 (28.2%) 0.534
Atopic asthma
     Ever 12 (5.3%) 10 (5.6%) 0.890
     Current use of inhalators 6 (2.7%) 5 (2.8%) 0.923
     Family history 56 (25.0%) 43 (24.3%) 0.891
Hay fever
     Ever 38 (16.9%) 18 (15.8%) 0.774
     Current use of nasal spray / antihistaminics 37 (17.6%) 26 (14.7%) 0.437
     Family history 89 (39.6%) 67 (37.9%) 0.725
Any atopic disorder 60 (26.7%) 44 (24.9%) 0.681
This association yielded an unadjusted OR 0.32 95%CI[0.14-0.73] and after 
adjusting for age, ancestry and sex this was OR 0.30 95%CI[0.13-0.71] (Table 3).
Table 3. Uni- and multivariate logistic analyses of the risk of sarcoidal uveitis. 
n = 402 Unadjusted OR (95% CI) Adjusted* OR (95% CI)
Eczema 0.32 (0.14-0.73) 0.30 (0.13-0.71)
Age, yr (per 10 yr) 1.12 (0.95-1.31) 1.16 (0.98-1.37)
Dutch ancestry 0.50 (0.31-0.79) 0.50 (0.31-0.81)
Male sex 0.42 (0.27-0.66) 0.42 (0.27-0.67)
Adjusted for all the variables in table 3.
CI = confidence interval; OR = odds ratio.
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Sarcoidosis in atopic patients
We also analyzed the differences in the activity and the severity of sarcoidosis in 
atopic and non-atopic patients. No statistically significant differences were found 
in the distribution of serum ACE, calcium, erythrocyte sedimentation rate, T-cell 
numbers and lung function tests (TLC, FVC, FEV1 and TLCO; Table 4). The 
HCRT modified Scadding scores were comparable between atopic and non-
atopic sarcoidosis patients. A history of atopic diseases did not affect resolution 
rates (15% vs. 20%, p=0.895), TNF-alpha blocker use (20% vs. 21%, p=0.8990 
and methotrexate use (20% vs. 30%, p=0.340) among patients with sarcoidosis.
Table 4. Pulmonary sarcoidosis activity and severity in atopic vs 
nonatopic patients at the time of diagnosis sarcoidosis. 
Any Atopy
n = 43
No Atopy
n = 123
p Value
Serum ACE, ug/L 52 (IQR, 26-112) 47 (IQR, 30-86) 0.325
Serum CA, mmol/L 2.35 (IQR, 2.29-2.43) 2.40 (IQR, 2.33-2.47) 0.211
Erythrocyte sedimentation rate, mm/hr 12 (IQR 6.0-24) 15 (IQR, 6.0-31) 0.958
T-cells, * 109/L 0.75 (0.41-1.02) 0.73 (IQR, 0.53-1.22) 1.000
Total lung capacity, %ref 86 (IQR, 68-97) 79 (IQR, 17-90) 0.297
Forced vital capacity, %ref 96 (IQR, 72-103) 100 (IQR, 89-112) 0.247
Forced expiratory volume in 1 s, %ref 86 (IQR, 64-99) 92 (IQR, 76-105) 0.938
Transfer factor for carbon monoxide/
diffusion capacity for carbon monoxide, %ref  
74 (IQR, 52-91) 72 (IQR, 52-82) 0.938
Sarcoidosis Scadding stage HRCT n = 39 n = 118
0 8 (21%) 18 (15%)
1 7 (18%) 38 (33%)
2 15 (38%) 44 (37%)
3 4 (10%) 5 (4%)
4 5 (13%) 13 (11%) 0.341*
* The p value for trend.
IQR = interquartile range; HRCT = high-resolution computed tomography; ACE = angiotensin-converting
enzyme; %ref = expressed as percentage of reference group.
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Discussion
No association between atopy and the development of sarcoidosis was found in 
this study. Having an atopic disorder was also not associated with attenuated 
disease. However, atopic eczema is associated with a lower occurence of 
sarcoidal uveitis. This strong negative association remained after 
adjusting for confounders. 
Our study also confirmed the classic risk factors (black race and female sex) for 
sarcoidosis. Sarcoidosis is currently perceived as a Th1-mediated disease, whereas 
atopic disorders are categorized as exclusively Th2 conditions. Antagonism between 
Th1 and Th2 axes has been the subject of previous studies and atopy has 
been linked to a lower prevalence and a less severe course of auto-immune 
diseases like diabetes mellitus type-1, rheumatoid arthritis and multiple sclerosis 
(16). The ACCESS (A Case Controlled Etiologis Study of Sarcoidosis) study 
also revealed that sensitization to household animal dust and feathers 
conferred a lower risk for the development of sarcoidosis (17). 
  The Turkish and the Japanese studies  reported a lower prevalence 
of positive tests for atopy, including skin prick tests and total serum 
IgE levels in subjects with sarcoidosis (4, 5). In contrast, another questionnaire 
based study performed in New Zealand did not confirm these 
findings (18). Questionnaire-based studies may be more appropriate in this 
setting as atopic disorders, especially atopic eczema, are generally more active 
during childhood. Moreover, negative skin prick tests and lower total serum IgE 
levels may reflect an anergy of sarcoidosis instead of an absence of atopy. Anergy in 
sarcoidosis is a well-recognized phenomenon. Nevertheless, no single impairment 
has been pinpointed to be the cause. The anergy of sarcoidosis has been ascribed 
to the generally increased numbers of Tregs (19) and inert dendritic cells (20). 
Clinically, it results in reduced efficacy of vaccination (21) and suppression 
of cell mediated hypersensitivity (22-24). It is plausible that this anergy affects 
the expression of atopy or reactivity to in vivo and in vitro atopy tests.
  Our results showed that atopic eczema was negatively associated 
with uveitis. How eczematous skin may contribute in the protection 
of physically and immunologically isolated eyes is not clear from 
this study. This association was independent of traditional risk factors 
gender and ancestry which suggests a non-genetic effect. However 
this unexpected finding warrants replication in other studies.
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The major weakness of our data are the dependence of self-reporting 
and retrospective assessment, with inherent recall bias. This is due to the nature 
of atopic disorders which mostly tend to wane in the adulthood. Recall 
bias could have played a role in the reporting of atopy. In addition, we 
have reported a cohort of patients referred to our university clinic with 
a relatively high incidence of uveitis which could also bias our results.
  This is the first controlled study assessing the history of atopy. This is also 
the first study of sarcoidosis and atopy to take into account the three major types 
of sarcoidosis patients. The prevalence of atopic features in our control group is in 
concordance with prevalence found in a previous study (15). In future studies 
we recommend further investigation into the association of sarcoidosis uveitis 
and atopic eczema and if confirmed, investigation of the possible mechanisms.
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Abstract
Purpose
Sarcoidosis is a multisystem granulomatous disorder, most frequently 
involving the lungs, skin, or eyes. Somatostatin receptor scintigraphy 
(SRS) can visualize sarcoid granulomas through binding of a 
radionuclide-coupled somatostatin analog to somatostatin receptors 
that are expressed in sarcoidosis. Uptake and patterns on SRS were 
studied and correlated to clinical and conventional findings.
Methods
Data of 218 SRSs undertaken for the analysis of potential sarcoidosis were 
studied. These scintigraphies were retrospectively studied on intensity uptake 
degrees and  localization of sarcoidosis-associated lesions, and compared 
with conventional radiological techniques (chest x-ray and CT). 
Results
In all but 1 of the 175 evaluable patients, SRS demonstrated uptake. In patients 
with thoracic sarcoidosis-associated lesions, SRS improved the yield of 
visualization of chest x-ray in 20 (36%) and CT in 7 (32%) of 
histologically unproven patients, and in 31 (30%) and 8 (14%) of the 
histologically proven patients, respectively. Mediastinal lesions together 
with either eye, salivary glands, clavicular, or hilar localizations were 
most frequent demonstrated on SRS and constituted characteristic patterns. 
Exclusive extrapulmonary disease was found in 6% of the patients. 
Conclusions
Somatostatin receptor scintigraphy enhances the yield of investigations in 
sarcoidosis patients and therefore provides a useful and sensitive imaging 
technique to monitor organ involvement and therapeutic efficacy
in patients with sarcoidosis.
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Introduction
Sarcoidosis is a multisystem disease of unknown origin and is located in > 90% 
intrathoracal (1). Traditionally, the diagnosis is based on compatible clinical and 
radiological findings (X-ray and CT-scan), the presence of non-caseating 
granulomas and exclusion of similarly presenting disorders (2). The yield of 
conventional imaging techniques can be augmented by novel radionuclear imaging. 
  Somatostatin receptor subtype 2 (sst2) is highly expressed in 
sarcoid granulomas and used as a substrate for somatostatin receptor scintigraphy 
(SRS) with 111In-DTPA-D-Phe1-octreotide, and the pendant in 
PET-imaging with 68Gallium labelled somatostatin analogues (3-6). 
111In-DTPA-D-Phe1-octreotide shows a high affinity for the sst2 receptor 
and can therefore be used in the imaging of sarcoidosis (7).
  Previous studies with SRS showed improved imaging in sarcoidosis 
(8, 9). So far, it is however scarcely studied in what percentage of patients 
the yield of clinical evaluations can be extended by SRS. The aim 
of this retrospective study was to evaluate the additive value in 
the clinical evaluation and determination of sarcoidosis by SRS.
Material and methods
Patients 
This retrospective study included 218 patients of the Clinical Immunology 
outpatient clinic in the Erasmus University Medical Center 
that had SRS because of a clinical suspicion or follow up for sarcoidosis 
between June 1991 and June 2010 (Table 1). 
  Sarcoidosis was diagnosed according to the guidelines of the American 
Thoracic Society/European Respiratory Society/World Association of 
Sarcoidosis and other Granulomatous Disorders statement on sarcoidosis 
(10). Exclusion criteria were a diagnosis other than sarcoidosis, 
steroid therapy during SRS  or resolved disease (Figure 1).
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Table 1. Patient characteristics of 175 patients with sarcoidosis.
Age in years (SD) 52 (13)
Disease duration in years (range) 2.6 (0-35)
Sex
   Female 101
   Male 74
Race
   White 119
   Black 56
Histological proof for sarcoidosis
  Yes 109
   No 66
Negative SRS 1
1 localization on SRS 10
More than 1 localization on SRS 164
Somatostatin receptor scintigraphy
The scintigrams of all 218 patients were initially examined by nuclear 
medicine physicians and for this study independently re-examined by 
an investigator (L.S.K.) with supervision of a senior nuclear medicine 
physician (D.J.K.), without knowledge of the medical history or outcome 
of other investigations. Uptake of radioactivity in disease-related areas 
was graded on a four-point scale: 0, no uptake; 1, intensity less
than that of the liver; 2, intensity identical to that of the liver; 3, intensity greater 
than that of the liver (8). Disease activity was scored for the following localizations: 
mediastinum, hila, lung parenchyma, extra pulmonary lymph nodes, central 
nervous system, eye, nose, salivary glands, oral mucosa, 
heart, skin, muscles and joints.
Conventional imaging
Conventional imaging of the chest (X-ray or CT-scan) was available for 158 
patients. Chest X-rays (CXR) results were classified according the Scadding 
system (11, 12). The time interval between SRS and conventional imaging 
was less than 3 months and in a similar clinical situation, without change 
in clinical course or intervention with therapeutic agents (13,14). 
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Figure 1. Inclusion algorithm.
Schematic view of 218 included patients undergoing a SRS in the event of evaluation for sarcoidosis. 
Diagnosis of the 22 non-sarcoidosis patients included SLE (1), MS (1), idiopathic uveitis without signs of 
extra ocular disease (1), tuberculosis (1), fibromyalgia (1), idiopathic small fibre neuropathy (1), medullary 
thyroid carcinoma (1), granulomatous tattoo reaction (1), unspecified granulomatous dermatitis (1), Crohn’s 
disease (1), granulomatous vasculitis surrounding sural nerve (presumably local eosinophilic granulomatosis 
with polyangiitis 1), inflammatory orbital process (1), carcinoid (1), idiopathic erythema nodosum 
(2), Sjögren’s disease (1), polymyalgia rheumatica (1), gout (1), rheumatoid arthritis (1) or none (3).
Statistics
Statistical analyses were performed using the one-way ANOVA 
test and χ2 test for categorical data (SPSS version 18.0). A 
P-value < 0.05 was considered statistically significant.
Chapter 3
72
Results
Patients
Out of the 218 patients analysed by SRS, 175 patients were included (Figure 1).
Patient characteristics are summarized in Table 1. Granulomas could be 
demonstrated in 109 patients. The details for exclusion of the 43 patients are given 
in Figure 1. Of the 12 patients on prednisone 6 still demonstrated SRS uptake.
Localizations and typical patterns of distribution of radioactivity on SRS
Ten patients had one localization and 165 patients had more than one 
localization on SRS (Table 1). Figures 2 and 3 demonstrate examples of 
positive and negative SRS and the frequency of involved sites are 
summarized in Table 2. Table 3 shows significant patterns in sarcoidosis. 
Table 2. Sarcoidosis involvement in 175 patients on SRS.
Involved Sites n (%)
Thoracic 165 (94)
   Hilar 118 (71)
   Mediastinal 78 (47)
   Lung parenchyma 63 (38)
Central nervous system 11 (6)
Eye 39 (22)
Nose 44 (25)
Salivary glands 58 (33)
Oral mucosa 3 (2)
Axillae 20 (11)
Clavicular 14 (8)
Heart 7 (4)
Inguinal 32 (18)
Skin 11 (6)
Muscle 1 (1)
Joints 17 (10)
Localization of SRS uptake in sarcoidosis patients evaluated with SRS.
Italic value is important to make clearly differentiate between all involved pulmonal sites and a subdivision of 
pulmonal sites. 
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SRS can enhance the yield of conventional imaging techniques
In both histologically proven and unproven sarcoidosis (109 and 66, 
respectively) all but one SRS demonstrated uptake. In the negative scan, 
granulomas were histologically demonstrated in hepatic portal lymph 
nodes where normal hepatic SRS uptake influences differentiation. In this 
case the initial radio nuclear medicine physician did report probable 
uptake probably in portal lymph nodes. This could initially not be visualized 
by ultrasonography, but later was confirmed by CT. The blinded researcher 
(L.S.K.) did not detect SRS uptake, hence the SRS was scored 0.
Figure 2. Examples of planar images of SRS.
A; no pathological uptake. B; pathological uptake is present in nose, lacrimal, parotid and submandibular glands, 
neck, mediastinum, hila, axillae, inguinal lymph nodes and skin. C; pathological uptake is present bilateral in the 
parotid glands and in mediastinum. D; nose, lacrimal glands, parotid and submandiblar glands with 
pathological uptake with bilateral pathological uptake in the supraclavicular, axillae, mediastinal and inguinal lymph 
nodes. In all images physiological bowel contamination and urinary bladder activity are seen in the abdomen.
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SRS is superior in imaging than conventional imaging in thoracic 
sarcoidosis
In the histologically unproven patients, the combination of laboratory and/or 
bronchial fluid findings, typical patterns on radiological imaging combined to 
the SRS results established the diagnosis of sarcoidosis. Comparison of the SRS 
with conventional radiological imaging of the thoracic region showed that SRS 
augmented the yield. Respectively 56 and 22 CXR or CT could be compared with 
SRS. SRS improved the yield in 20 (36%) and 7 (32%) of those patients, 
respectively. CT did not add more positive results to the CXR (data not shown). 
  In the histological proven group respectively 102 and 59 
patients had concomitant SRS and CXR or SRS and chest CT. There 
were no negative SRS in this group. SRS improved the visualization of 
thoracic localization in 31 (30%) and 8 (14%) patients, respectively (Table 4). 
Apart from granuloma localization, Figure 3 demonstrates a correlation 
of clinical activity of sarcoidosis with therapeutic efficacy.
Table 4. SRS compared to conventional imaging in patients with 
histologically proven sarcoidosis.
SRS-Conv  n = 109 SRS + SRS-
  Conv + 102 1
  Conv - 6 0
SRS-CXR n = 102  SRS + SRS -
  CXR + 71 0
  CXR - 31 0
SRS-CT n = 59  SRS + SRS -
  CT + 51 0
  CT - 8 0
CT-CXR n = 59  CXR + CXR -
  CT + 42 8
  CT - 0 9
In 109 histological proven sarcoidosis patients conventional (Conv) techniques were 
compared in the establishment of the diagnosis. By use of SRS scans thoracic localizations 
were found in 102 patients and compared to either chest X-ray (CXR) or CT of the chest (CT).
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Figure 3. SRS prior and after treatment with corticosteroids.
This patient, a woman of 37 years, was treated with corticosteroids for a period of 16 months and showed a 
good clinical response of this treatment on SRS. Her signs of shortness of breath and fatigue disappeared. 
Pathological uptake in the first image is present in nose, lacrimal, parotid and 
submandibular glands, neck, mediastinum, hila, lung parenchyma, axillae and inguinal lymph nodes. 
Fibrosis 
52 patients had lung parenchyma uptake on conventional imaging and 
77 patients on SRS. Of the patients that were SRS positive, but negative 
on conventional thoracic imaging techniques, 5 developed pulmonary 
fibrosis shown on CT-scan ranging 3 - 8 years after SRS. 
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Discussion
In this retrospective study, we demonstrate that SRS is additional in 
the diagnostic work-up and more sensitive than conventional imaging 
in sarcoidosis patients. The observations underscore that sarcoidosis 
is a systemic disease that can be visualized by this technique.
  The characteristic panda sign with lacrimal and parotid glands uptake 
and abundant hilar, mediastinal or lung parenchyma involvement observed in 
the present study (Table 3) is in line with the literature (15). The remarkable high 
percentage of 33% positive salivary glands indicates that sarcoidosis could 
be present without clinical visible signs, e.g. enlarged salivary glands (13). 
  Hilar and/or mediastinal lymph node involvement observed on 
chest X-ray or CT-scan could be confirmed by SRS in every case in this 
study. SRS revealed significantly more thoracic lesions than conventional 
radiologic scans, substantiating previous but smaller studies (8). 
Our observations hence indicate that sarcoidosis patients may 
remain undetermined with conventional imaging and underscore the 
assumption that negative conventional imaging for sarcoidosis does 
not exclude pulmonary involvement. 
  SRS may be a tool to monitor efficacy of treatment in sarcoidosis, 
however patients on steroids must be excluded since treatment with 
corticosteroids down regulates the sst2 receptor and half of our patients on 
steroids still demonstrate SRS uptake (16). Five of the 63 patients with lung 
parenchyma uptake on SRS developed fibrosis after SRS. All 5 had no signs 
of pulmonary sarcoidosis on the conventional techniques, but all had signs 
of pulmonary involvement on SRS. To establish if certain patterns on SRS 
are predictive for developing fibrosis in sarcoidosis, more numbers need 
to be included. However, although the number of patients with diffuse 
lung involvement is limited in our study, our data could suggest that without 
lung parenchyma uptake on SRS, no pulmonary fibrosis will occur. 
  SRS is superior to conventional imaging and can therefore be of
use as an additive tool in the detection and also in monitoring of 
patients suspected and treated for sarcoidosis. It might be of interest to 
extrapolate scintigraphic observations with bio-immunological markers, 
such as soluble IL-2 receptors or CD subset-analyses, in order to define 
the extent of disease and predict therapeutic success (17, 18).
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Therapy
4.1
Calcium and vitamin D in sarcoidosis: is supplementation 
safe?
Kamphuis LS, Bonte-Mineur F, van Laar JA, van Hagen PM, 
van Daele PL 
J Bone Miner Res. 2014;29:2498-2503
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Abstract
Granulomas in sarcoidosis express high levels of 1α-hydroxylase, an enzyme 
that catalyzes the hydroxylation of 25-OH vitamin D to its active form, 
1,25(OH)2 vitamin D. Overproduction of 1α-hydroxylase is held responsible 
for the development of hypercalcemia in sarcoidosis patients. Corticosteroids 
are used as first-line treatment in organ-threatening sarcoidosis. In this 
light, osteoporosis prevention with calcium and vitamin D (CAD) 
supplementation is often warranted. However, sarcoidosis patients are at 
risk for hypercalcemia, and CAD supplementation affect the calcium metabolism. 
We studied calcium and vitamin D disorders in a large cohort of sarcoidosis 
patients and investigated if CAD supplementation is safe. 
Methods
Retrospectively, data of 301 sarcoidosis patients from July 1986 to June 2009 
were analyzed for serum calcium, 25-hydroxy vitamin D (25-(OH)D), 
1,25-dihydroxy vitamin D (1,25(OH)2D), and use of CAD supplementation. 
Disease activity of sarcoidosis was compared with serum levels of vitamin D.
Results 
Hypercalcemia occurred in 8%. A significant negative correlation was found 
between 25-(OH)D and disease activity of sarcoidosis measured by 
somatostatin receptor scintigraphy. In our study, 5 of the 104 CAD 
supplemented patients developed hypercalcemia, but CAD supplementation 
was not the cause of hypercalcemia. Patients without CAD supplementation 
were at higher risk for developing hypercalcemia. During CAD 
supplementation, no hypercalcemia developed as a result of supplementation. 
Hypovitaminosis D seems to be related with more disease activity of sarcoidosis 
and, therefore, could be a potential risk factor for disease activity of 
sarcoidosis. Thus, vitamin D-deficient sarcoidosis patients should be 
supplemented.
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Introduction 
Sarcoidosis is a multisystem disease of unknown cause characterized by the 
presence of activated T cells, mononuclear phagocytes and non-caseating 
granulomas (1). Most patients with sarcoidosis do not need treatment. 
However in cases of organ-threatening sarcoidosis, corticosteroids are used as 
first-line treatment (1). Osteoporosis prevention with bisphosphonates and/or 
calcium and vitamin D (CAD) supplementation is advised in patients starting 
a course of daily 7.5 mg prednisone or higher for 3 months or longer (2). 
  In 1939 Harrell et al. first described hypercalcemia in sarcoidosis (3). 
The prevalence of hypercalcemia in patients with sarcoidosis is approximately 
5 to 11% (1, 4, 5). Activated macrophages in sarcoid granulomas are capable 
to upregulate extrarenal 1α-hydroxylase, the enzyme which converts 
25-hydroxy vitamin D (25-(OH)D) to its active form, 1,25-dihydroxy vitamin D 
(1,25(OH)2D). This can result in hypercalcemia (6). Other mechanisms for 
hypercalcemia in sarcoidosis are expression of parathyroid hormone-related 
protein (PTH-rP) in sarcoid macrophages what may exert an autocrine action 
of 1 α-hydroxylase activity and increased levels of serum interferon (IFN)-γ 
(7-10). IFN-γ stimulates the production of 1,25(OH)2D 
by alveolar macrophages (11). 
  In this retrospective study we examined in a large group of sarcoidosis 
patients the levels of calcium and vitamin D, its association with disease activity 
and we investigated whether CAD supplementation increased 
the risk of hypercalcemia.
Material and methods 
Patients
This retrospective study included all sarcoidosis patients who visited the 
Clinical Immunology outpatient clinic in the Erasmus University Medical 
Center between July 1986 and June 2009. A total of 301 patients were included. 
Sarcoidosis was diagnosed according to the guidelines of the American 
Thoracic Society/European Respiratory Society/World Association of 
Sarcoidosis and other Granulomatous Disorders statement on sarcoidosis (12). 
Data was collected using the computerised hospital information system and 
medical records. Patients were studied until last visit, loss to follow-up or death.
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Laboratory analysis
Serum levels of calcium, 25-(OH)D and 1,25(OH)2D were measured 
in respectively 293, 183 and 172 samples obtained from sarcoidosis 
patients at moment of diagnosis. Serum calcium levels were corrected 
for serum albumin. Serum levels of 25-(OH)D and 1,25(OH)2D 
were measured using radioimmunoassays (IDS Ltd, Boldon, UK).
Imaging techniques
Disease activity of sarcoidosis was measured by chest X-ray and somatostatin 
receptor scintigraphy (SRS), in respectively 111 and 70 patients. Chest X-rays 
were classified according the Scadding system in five stages (13, 14). Stage 0, 
normal appearance; stage 1, bilateral hilar lymphadenopathy alone; stage 2, 
bilateral hilar lymphadenopathy and parenchymal shadowing; stage 3, 
parenchymal shadowing alone; stage 4, fibrosis. SRS uptake was graded on a 
four-point scale: 0, no uptake; 1, intensity less than that of the liver; 2, intensity 
identical to that of the liver; 3, intensity greater than that of the liver (15).
CAD supplementation
Patients treated with CAD supplementation were retrospectively selected from 
the included patients. The doses of CAD supplementation varied, but most 
patients used 500 mg calcium and 400 IU vitamin D daily. Of those patients 
disease activity of sarcoidosis, serum levels of calcium, 25-(OH)D and 
1,25(OH)2D and possible malignancies were retrieved from the medical record. 
Statistics
Statistical analyses were performed using the Pearson correlation 
method, one-way ANOVA test and Fisher’s exact test using SPSS 
version 20.0. A P-value < 0.05 was considered statistically significant. 
Results
In this retrospective study, 301 sarcoidosis patients (174 women and 
127 men) were included. 
  Of the 301 patients, 293 patients had serum calcium 
measured at the time of diagnosis. Hypercalcemia was found in 23 
patients (8%) and 4 of those 23 patients had high levels of 1,25(OH)2D.
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Mean levels of 25-(OH)D did not significantly differ between the hypercalcemic 
and non-hypercalcemic patients, respectively 43 nmol/l and 47 nmol/l, 
p = 0.58). 27 patients had hypocalcemia, 17 of those 27 patients had low levels 
of 25(OH)D and none had low levels of 1,25(OH)2D. Serum 25-(OH)D levels 
were low in 115 of the 183 patients (63%). No patient had 25-(OH)D levels 
above the upper level of normal. In 172 patients serum levels of 1,25(OH)2D 
were measured at diagnosis. In 14 patients (8%) serum levels of 1,25(OH)2D 
were elevated. Five patients (3%) had low active vitamin D levels. 
Hypercalciuria, defined as a urinary calcium excretion > 5.0 mmol/l, was found 
in 24 patients (27%) of the 89 patients. Data are listed in Table 1A and 1B.
Table 1A. Patients characteristics of 301 sarcoidosis patients and results 
of measurements.
Number of patients Prevalence (%)
Sex
     Female 174 58
     Male 127 42
Total measured serum calcium 293
     Normocalcemia 243 83
     Hypercalcemia 23 8
     Hypocalcemia 27 9
Total measured urine calcium 89
     Normocalciuria 65 73
     Hypercalciuria 24 27
Total measured 25-(OH)D 183
     Normal 25-(OH)D 68 37
     Low 25-(OH)D 115 63
Total measured 1,25(OH)2D 172
     Normal 1,25(OH)2D 153 89
     High 1,25(OH)2D 14 8
     Low 1,25(OH)2D 5 3
Measurements of various calcium related parameters in 301 patients diagnosed 
with sarcoidosis. Samples were taken at moment of diagnosis.
Serum levels of calcium were not significantly correlated with either 
25-(OH)D, nor 1,25(OH)2D levels (r = -0.05, p = 0.52 and r = 0.14, p = 0.07 
respectively). A significant relation was found between serum levels of 
25(OH)D and 1,25(OH)2D, respectively r = 0.36, p < 0.001 (Figure 1).
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Table 1B. Patients characteristics of 301 sarcoidosis patients and results 
of measurements. 
Number of patients Mean value (95% confidence interval)
Total group 301
     Calcium 293 2.35 mmol/l (2.33 – 2.37)
     25-(OH)D 183 46 nmol/l (43 – 50)
     1,25(OH)2D 172 111 pmol/l (104 – 117)
CAD group 104
     Calcium 67 2.39 mmol/l (2.25 – 2.52)
     25-(OH)D 59 42 nmol/l (29 – 56)
     1,25(OH)2D 53 114 pmol/l (99 – 129)
Not CAD group 197
     Calcium 226 2.34 mmol/l (2.29 – 2.38)
     25-(OH)D 124 46 nmol/l (39 – 49)
     1,25(OH)2D 119 112 pmol/l (102 - 121)
CC group 182
     Calcium 184 2.38 mmol/l (2.30 – 2.46)
     25-(OH)D 104 47 nmol/l (37 – 57)
     1,25(OH)2D 98 109 pmol/l (93 – 125)
Not CC group 119
     Calcium 109 2.34 mmol/l (2.29 – 2.39)
     25-(OH)D 79 46 nmol/l (42 – 53)
     1,25(OH)2D 74 111 pmol/l (94 – 120)
Normal values: serum calcium, 2.20-2.65 mmol/l; 25-(OH)D: 50-136 nmol/l; 1,25(OH)2D: 38-183 pmol/l.
No correlation was found between serum levels of calcium and sarcoidosis 
stadium on chest X-ray. Notably, a significant negative relation was found between 
serum level of 25-(OH)D and uptake on SRS, p < 0.001 (one-way ANOVA, Figure 2).
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Figure 1. Correlations of the calcium and vitamin D metabolism in 
sarcoidosis patients.
A. In 183 patients no correlation between serum level calcium and 25-(OH)D was found (r = -0.05, p = 0.52). 
B. In 172 patients no statistically significant correlation was found for serum level calcium and 1,25(OH)2D 
(r = 0.14, p = 0.07). 
C. A significant relation was found between serum levels of 25(OH)D and 1,25(OH)2D (r = 0.36, p < 0.001).
Chapter 4
86
Figure 2. Correlation between serum 25-(OH)D and SRS uptake grade.
A significant correlation (one-way ANOVA) was found between uptake grade 
of SRS and serum level 25-(OH)D (p = 0.016). 
Uptake of radioactivity in disease-related areas was graded on a four-point scale: 0, no uptake; 1, intensity 
less than that of the liver; 2, intensity identical to that of the liver; 3, intensity greater than that of the liver
Normal value: 25-(OH)D, 50-136nmol/L.  
During follow-up 182 patients were treated with corticosteroids. Of these 182, 
a total of 65 patients received CAD supplementation (average dose of CAD 
supplementation 1.25g/400IE). Additionally, 39 patients received CAD 
supplementation without corticosteroid treatment (Figure 3). Of the 104 
patients treated with CAD, 5 patients developed hypercalcemia. Three of these 
5 patients had evidence of exacerbation of sarcoid-activity at time of diagnosis 
of hypercalcemia. One patient had hypercalcemia due to primary 
hyperparathyroidism and in one patient CAD supplementation was started at 
moment of hypercalcemia resulting in a more severe hypercalcemia. None 
of those 5 patients had elevated 25-(OH)D or 1,25(OH)2D levels (Table 2).
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Figure 3. Flow chart of safety of CAD supplementation in sarcoidosis 
patients.
Using the Fisher’s exact test for developing hypercalcemia during CAD
supplementation a p-value for sarcoidosis patients treated with 
corticosteroids of p = 0.61 and a p-value of p < 0.001 for patients 
without corticosteroids treatment was found.
  An additional 99 patients with CAD supplementation never 
developed hypercalcemia during follow-up. Mean levels of 25-(OH)D and 
1,25(OH)2D prior to CAD supplementation of the 99 patients were 
respectively 42 nmol/l and 114 pmol/l. 14 patients developed hypercalcemia 
without receiving corticosteroids and CAD supplementation.
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Table 2. Patients with hypercalcemia during calcium and vitamin D 
supplementation.
Calcium PTH 25-(OH)D 1,25(OH)2D Treatment* Reason of hypercalcemia
1 2.86 0.3 31 75 CAD Exacerbation of sarcoidosis
2 3.37 9.7 34 143 CAD Primary hyperparathyroidism
3 2.72 0.7 34 58 CAD, CC Hypercalcemia at start of CAD 
4 3.62 0.3 59 122 CAD, HCQ Exacerbation of sarcoidosis
5 3.12 n.d. 44 22 CAD, CC Exacerbation of sarcoidosis
Average dose of calcium and vitamin supplementation of the above mentioned patients is 1.25g/400IE.
Definition of abbreviations: CAD = calcium and vitamin D supplementation; CC = corticosteroids; 
HCQ = hydroxychloroquine; PTH = parathyroid hormone; n.d. = not done.
Normal values: calcium = 2.20-2.65 mmol/l; PTH = 1.4-7.3 pmol/l; 25(OH)D = 50-136 nmol/l; 
1.25-(OHD)2D = and 38-183 pmol/l.
Bold = abnormal values; * = treatment at moment of diagnosis hypercalcemia. 
Serum calcium level is corrected for albumin. 
An additional 99 patients with CAD supplementation never developed 
hypercalcemia during follow-up. Mean levels of 25-(OH)D and 1,25(OH)2D 
prior to CAD supplementation of the 99 patients were respectively 42 nmol/l 
and 114 pmol/l. 14 patients developed hypercalcemia without receiving 
corticosteroids and CAD supplementation. Mean levels of 25(OH)D and 
1,25(OH)2D of the 14 patients who developed hypercalcemia without 
receiving corticosteroids and CAD supplementation were respectively 
53 nmol/l and 178 pmol/l. The non-hypercalcemic patients without receiving 
corticosteroids and CAD supplementation had mean levels of 48 nmol/l 
and 108 pmol/l. In the whole non-hypercalcemic group mean levels 
of 25(OH)D and 1,25(OH)2D were 82 nmol/l and 151 pmol/l. 
  The 104 patients with CAD supplementation had mean levels of 
25-(OH)D of 46 nmol/l prior to supplementation. Low levels of 25-(OH)D 
were found in 66 patients. In total the serum level of 25-(OH)D increased by 
28nmol/l in the total group of 104 CAD patients. In Figure 3 a flow chart 
of CAD supplementation safety in sarcoidosis patients is shown. There 
was no significant difference in the risk of developing hypercalcemia 
between the patients using CAD as compared to those not using CAD. 
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Discussion
In this retrospective study, we examined the prevalence of calcium 
and vitamin D disorders in sarcoidosis patients and its association 
with disease activity. Furthermore we investigated if CAD 
supplementation is safe in patients diagnosed with sarcoidosis. 
  Hypercalcemia frequently occurs in sarcoidosis (4, 5). In earlier reports 
of Conron et al. and Adler et al., it is estimated that hypercalcemia occurs in 5 
to 10 percent (4, 5, 16). In our cohort a comparable number of 8% was found. 
  Remarkable was the high number of patients with decreased serum levels 
of 25-(OH)D (63%). Although there is no consensus on optimal serum levels of 
25-(OH)D. Vitamin D deficiency is defined by most experts as a 25-(OH)D 
serum level of less than 50 nmol/l, as was in our study (17). Sarcoidosis is most 
frequently diagnosed in the winter months, when vitamin D levels are at their 
lowest (18). The value of serum level 25-(OH)D in our study was measured at 
moment of diagnosis, thus mostly in the winter. However, a recent study of 
Powe et al. investigated the role of free 25-(OH)D (19). In this study it was 
concluded that levels of free 25-(OH)D were more correlated with the actual 
vitamin D deficient states than 25-(OH)D. Thus the total number of patients 
with decreased serum levels of 25-(OH)D found in our study could be lower. 
  Recent studies show that decreased levels of serum 25-(OH)D are a 
risk factor for higher disease activity in several inflammatory diseases such as 
Crohn’s disease and multiple scleroris (17, 20, 21). In our study disease 
activity of sarcoidosis measured by SRS correlated negatively with serum 
levels of 25-(OH)D. Vitamin D is an important immunomodulator that may 
have a positive effect in patients with sarcoidosis (22). Thus low serum level of 
25-(OH)D could be a potential risk factor for disease activity in sarcoidosis 
and supplementation of vitamin D in cases of deficiency could be beneficial. 
  In our study 104 patients were on CAD supplementation. Only 5 of the 
104 CAD suppleted patients developed hypercalcemia and none of these 5 had 
elevated 1,25(OH)2D levels. So CAD supplementation appears to be safe. This 
is in accordance with much smaller studies by the group of Adler et al. who 
analyzed 26 patients with sarcoidosis on CAD supplementation and a recent 
study of Bolland et al. in which 27 sarcoidosis patients were analyzed (5, 16). 
Different from our study, all patients in Adler’s study were Afro-Americans.
Afro-Americans have a higher prevalence of low serum 
25-(OH)D levels than Caucasians and the possibility to develop 
hypercalcemia for a Afro-American is lower (23).
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In our study most patients were Caucasian, a group who is more at risk for 
developing hypercalcemia (23). Of the 5 patients who developed hypercalcemia 
during CAD supplementation, 4 patients had this event without having 
primary hyperparathyroidism. 3 of those 4 patients were vitamin D deficient 
and 2 received corticosteroids at the same time. The use of corticosteroids 
may prevent increases in 1,25-(OH)2D in response to CAD supplementation. 
Thus in patients who are receiving CAD supplementation and corticosteroids 
at the same time, levels of serum calcium could higher than measured.
  In our study sarcoidosis patients without CAD supplementati
on were at higher risk for developing hypercalcemia, without having a 
significant difference of serum level of 25-(OH)D between the CAD and 
nonCAD treated Group, (Figure 3). As mentioned before, vitamin D 
deficiency could possibly increase the disease activity of sarcoidosis. 
Thus the results of our study suggest that vitamin D deficient sarcoidosis 
patients should be suppleted with CAD to potentially lower disease activity.
  Hypovitaminosis D and osteoporosis prophylaxis are the main reasons 
to supply sarcoidosis patients with CAD. Vitamin D intoxication is extremely 
rare but can be caused by high doses of vitamin D and induces hypercalcemia 
(17). The recommended daily intake of vitamin D is 200IU daily for adults 
up to 50 years of age, 400 IU for adults 51 to 70 years of age and 600 IU for 
adults 71 years of age or older (17). Doses of more than 50,000 IU per day 
are associated with hypercalcemia (17). Vitamin D doses of 10,000 IU per 
day for a period of 5 months resulted not in toxicity (24). Patients in our 
study used mostly 400 IU daily of vitamin D. Thus vitamin D intoxication 
is not expected if normal doses of CAD supplementation are used. 
  In conclusion our study demonstrates that serum levels of 25-(OH)D are 
negatively related with disease activity of sarcoidosis and that CAD supplementation 
is safe for sarcoidosis patients. These results indicate that lower serum levels of 
25-(OH) seems to be associated with higher disease activity of sarcoidosis. 
Therefore in case of vitamin D deficiency, CAD supplementation should be 
started. Our study provides a rationale for a systematic study on vitamin D 
therapy in sarcoidosis patients with active disease and vitamin D deficiency.
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4.2
Parts of this introduction are based on:
Efficacy of adalimumab in chronically active and 
symptomatic patients with sarcoidosis
Kamphuis LS, Lam-Tse WK, Dik WA, van Daele PL, van 
Biezen P, Kwekkeboom DJ, Kuijpers RW, Hooijkaas H, van 
Laar JA, Bastiaans J, Baarsma GS, van Hagen PM
Am J Respir Crit Care Med. 2011;184:1214-1216
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Abstract
Tumor necrosis factor-α (TNF-α) is associated with inflammatory 
symptoms of sarcoidosis patients.
Objectives 
To investigate clinical and biochemical effects of TNF-α blocking by 
adalimumab in chronically active systemic sarcoidosis patients. 
Material and methods 
In this observational study, five patients treated with 40 mg adalimumab every 
other week were studied throughout 12 weeks. All patients had chronic 
and active biopsy-proven systemic sarcoidosis averaging ten years. 
Results 
Therapeutic efficacy was monitored by computered tomography (CT)-scan, 
somatostatin receptor-scintigraphy (SRS), serum cytokine levels and 
questionnaires. Within 12 weeks adalimumab treatment yielded objective 
improvement in four out of five patients. Lymph nodes volumes on 
CT-scan decreased more than 15%. The kinetics of labeled somatostatin in 
lymph nodes on SRS tended to an attenuation of interferon-γ and interleukin-8. 
The questionnaires showed a significant improvement of fatigue.
Conclusions 
Four out of five patients responded to adalimumab treatment within 
12 weeks. This is the first study demonstrating both clinical and 
biochemical improvement after adalimumab in chronic sarcoidosis.
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Introduction
Sarcoidosis is a multisystem granulomatous immune mediated inflammatory 
disorder of unknown etiology (1). It can affect any organ in various degrees of 
severity. In a minority of patients the disease remains chronically active. 
Systemic immunosuppressive therapy is required in case of significant disease, 
detoriation of pulmonary function, cerebral or eye involvement or arthritis (1). 
Chronic sarcoidosis can result in secondary fibrosis in organs that are 
involved and may lead to invalidating and progressive organ failure (2).
  Granulomas, the pathological hallmark of patients with sarcoidosis, 
reflect the process of a complex inflammatory cascade. Activated macrophages 
and T helper (Th 1) lymphocytes are abundant and produce symptomatic 
(pro)-inflammatory cytokines such as tumor necrosis factor-α (TNF-α), 
interferon-γ (IFN-γ) and interleukin-1 (IL-1) (2). Other cytokines (IL-2, IL-8, 
IL-12, IL-15 and IL-18) may also be involved (2, 3). However, it is generally 
assumed that TNF-α is a key cytokine responsible for most of the inflammatory 
symptoms in sarcoidosis patients (2, 3). To date, the use of cytokines and 
cytokine receptors in monitoring disease activity of sarcoidosis is not established, 
however elevated levels of soluble IL-2 receptor (sIL-2R) in serum and 
bronchoalveolar lavage have been shown to be associated with active disease (4). 
  The use of immunosuppressives in sarcoidosis is hampered by adverse 
effects and lack of specificity. Considering the presumed important 
pathophysiological role of TNF-α, it might be an important target to block, 
hence improving therapeutic efficacy (5). Indeed, several favorable case reports 
and two randomized controlled trials (RCT’s) on TNF-α blocking agents 
have been published recently (6-17). The RCT of Baughman et al., describes 
the efficacy of infliximab in chronic sarcoidosis patients with pulmonary 
involvement, while a placebo-controlled study by Rossman et al., describes 
the effect of infliximab in patients with active pulmonary sarcoidosis (6, 7). 
Both studies demonstrate improvement of pulmonary function. 
  Infliximab is a chimeric humanized monoclonal TNF-α blocker 
which was administered in these studies every six-eight weeks intravenously 
under direct supervision by a health care team. Adalimumab, a fully human 
monoclonal antibody directed against TNF-α can be administered sub
cutaneously hence providing an alternative and more easy treatment option 
in an outpatient setting (5). Adalimumab treatment showed to be successful 
in patients with various immune mediated disorders, including rheumatoid 
arthritis (RA), Crohn’s disease (CD) and psoriasis. 
Chapter 4
96
We describe in this observational study the clinical and biochemical effects of 
adalimumab in patients with chronic systemic sarcoidosis evaluated with 
computerized tomography (CT)-scan, somatostatin receptor scintigraphy (SRS), 
pulmonary function tests (PFT), serum cytokine levels and questionnaires.
Methods  
Five biopsy-proven patients with chronically active and symptomatic sarcoidosis 
were included in this case-series. The average duration of sarcoidosis at the 
initiation of this study was 10 years (range 2-31 years). Patients were recruited 
between April 1 and June 30, 2009 from the outpatient clinic, patient 
characteristics are presented in Table 1. Other inclusion criteria included 
evaluable lesions on CT-scan, positive SRS and informed consent. Tuberculosis 
was excluded by history, chest X-ray, purified protein derivative test 
(PPD) and an interferon-gamma release assay (Quantiferon) (18). 
  Patients were excluded when concomitant immunosuppressives were 
used except hydroxychloroquine. Other exclusion criteria were HIV, HBV, HCV 
or Treponema pallidum, opportunistic or any other severe infection in the 
preceding two months; a malignancy within five years; lymphoproliferative disease; 
other systemic diseases; NYHA class III or IV congestive heart failure. 
Pregnancy, nursing or planning pregnancy 38 weeks after enrollment wasn’t allowed. 
  Sarcoidosis and CD both share similar symptoms and some identical 
pathological features, hence a CD schedule (baseline 160 mg, 80 mg at week 
2 and from week 4 onwards 40 mg every other week) was used (19). Initially, 
patients were instructed by a specialized nurse in the self-administration of 
adalimumab at home. Following a 12 week follow-up period patients were 
allowed to continue for a prolonged (> one year) period according to the 
treating physician’s decision. During the observation period, no additional 
therapy was started and dosages of currently used drugs were maintained. 
  Routine methods of evaluation included CT-scan, SRS, PFT (forced vital 
capacity, total lung capacity and diffusing capacity of carbon monoxide of the lung), 
laboratory analyses (blood cell counts, angiotensin converting enzyme (ACE), 
C-reactive protein (CRP), liver enzymes, albumin, calcium, lysozyme, 25-hydroxy 
vitamin D, 1.25-dihydroxy vitamin D, cytokines and physical examination.
  Radiological assessment included volume measurements 
of lymph nodes on the CT-scan and grading of uptake by SRS. 
The last twelve years the latter method became a reliable method to 
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visualize granulomas in sarcoidosis in our center.20 The intensity of pathologic 
uptake in the SRS was graded as follows: grade 0 = negative; grade 1 = intensity 
less than that of the liver; grade 2 = intensity same with that of the liver; 
grade 3 = intensity higher than that of the liver (20). Pulmonary involvement 
was classified by the Scadding system (21, 22). The volumes of multiple lymph 
nodes at one side (e.g. mediastinal nodes) were added together. Blood tests 
were regularly conducted. An enzyme-linked immunosorbent assay (ELISA, 
Diaclone, Besançon, France) was used to detect serum levels of sIL-2R. Serum 
levels of other cytokines were measured with cytometric bead arrays (CBA 
Human Inflammation Kit: IL-1β, IL-6, IL-8, IL-10, IL-12p70, TNF-α and 
the Human Th1/Th2 cytokine Kit: IL-2, IL-4, IL-5, IL-10, TNF-α, IFN-γ). 
 The fatigue was scored by using the Fatigue Assessment 
Scale (FAS) before treatment and at week 12.
  The data are presented as mean values ± standard deviation. 
Statistical analyses are performed using the paired samples t test (SPSS 
version 18.0). A P-value < 0.05 was considered statistically significant.
Table 1. Patient characteristics. 
Pt Age at Dx Age at Tx Gender Race Organ involvement Previous medication
1 43 48 F C Hilar/mediastinal lymphadeno-
pathy, lungs, skin
HCQ
2 38 39 F B Hilar/mediastinal lymphadeno-
pathy, lungs, skin, eyes, nose
Steroid eye drops
3 29 40 F B Hilar/mediastinal lymphadeno-
pathy, skin, parotid glands
Steroids, HCQ
4 27 58 M C Hilar/mediastinal lymphadeno-
pathy, small vessel neuropathy
Steroids, HCQ
5 74 76 M C Hilar/mediastinal lymphadeno-
pathy, lungs, eyes
HCQ, steroid eye drops
Abbrevations: Pt = patient; C = Caucasian; F = female; M = male; B = black; HCQ = hydroxychloroquine.
Results
Patients’ characteristics are summarized in table 1. All patients had both 
pulmonary and extra-pulmonary localizations of the sarcoidosis. 
  Table 2 displays the radiological findings during the observational 
period of 12 weeks. In four patients (patient 1-3, 5) radiologic improvement was 
observed. Patient 4 showed a mixed response. Enlarged thoracic and axillary 
lymph nodes decreased significantly (17.6% ± 14.3, P < 0.001) on the CT-scan. 
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Pathological uptake in sarcoidosis related lesions on the SRS decreased 
comparably and was felt to be even more sensitive than those of the CT-scan 
(Table 2 and Figure 1). Also dermatological involvement improved (Figure 2a, 2b). 
  PFT’s of all patients were normal at initiation of therapy 
and remained within normal limits (data not shown).
  During the observation, levels of ACE, CRP and calcium were within normal 
limits, whereas lysozyme levels were initially increased in patient 1, 2 and 5 
(range 14-21 mg/l) before treatment and returned to normal 
(< 12 mg/l) during treatment. Elevated serum sIL-2R levels occurred 
only in two patients and were subsequently disregarded for further 
evaluation (data not shown). The serum IFN-γ levels were elevated 
before treatment in four out of five patients (range 9.8-37.5). All 
patients had elevated IL-8 serum levels (range 14.4-31.8) before treatment.
Figure 1.
The CT scan and SRS of a patient with chronically active sarcoidosis before ((left) and 12 weeks after (right) TNF-α 
blocking therapy with adalimumab. Increased uptake in nose, salivary glands, and right axillary lymph node 
and mild uptake in hilar lymph nodes is demonstrated with SRS before treatment (left). The SRS 12 weeks 
after treatment (right) displays mild  uptake in the salivary glands. Note that although the size of cervical 
lymph nodes as displayed on CT scan remain almost equal, the uptake of these lesions on the SRS disappear.
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Table 2. Changes in radiographic imaging and fatigue after 12 weeks 
adalimumab treatment.
Pt Region CT-scan before 
(in mm)
CT-scan after (in 
mm)
Change in 
diameter
SRS 
before
SRS 
after
FAS score 
before
1 Submandibular 25.1 21.2 -15.5% 1 1 35
 Hilum 23.7 15.8 -33.4% 1 0  
 Mediastinum 20.0 15.9 -20.5% 0 0  
 Axillar 16.6 10.1 -39.2% 1 0  
 Inguinal 21.4 14.8 -30.8% 1 0  
 Skin    1 0  
2 Lacrimal gland 8.7 8.4 -3.4% 3 0 37
 Nose    3 0  
 Submandibular 17.7 13.4 -24.3% 2 1  
 Parotid glands 36.9 30.0 -18.7% 2 1  
 Hilum 16.9 14.0 -17.2% 2 1  
 Mediastinum 22.4 21.0 -6.2% 1 1  
 Axillar 15.2 7.0 -53.9% 1 0  
 Inguinal 19.5 17.1 -12.3% 2 1  
 Skin    2 1  
3 Lacrimal gland 13.4 10.9 -18.7% 1 0 25
 Nose    1 1  
 Submandibular 24.1 18.3 -24.1% 1 0  
 Parotid glands 40.3 38.6 -4.2% 2 2  
 Hilum    1 1  
 Mediastinum 24.2 24.2 0% 1 1  
 Axillar    0 0  
4 Hilum 9.9 10.1 +2.0% 0 0 34
 Mediastinum 8.5 8.3 -2.4% 0 0  
 Lung parenchyma    1 1  
 Joints    1 0  
5 Submandibular 20.7 16.5 -8.5% 1 0 24
 Hilum 20.8 16.8 -19.2% 2 1  
 Mediastinum 28.2 25.8 -20.3% 1 1  
Mean  20.7 17.1 -17.7 1.24 0.52 31
SD  8.0 7.8 13.9 0.8 0.6 6.0
Abbrevations: Pt = patient; CT = computer-tomography; SRS = somatostatin receptor scintigraphy; mm = 
millimeter; FAS = Fatigue Assessment Scale; SD = standard deviation. Nodes identified on CT-scan are listed 
in diameter (mm). The largest diameter of the node was measured. The intensity of pathologic uptake in the 
SRS was graded as follows: grade 0 = negative; grade 1 = intensity less than the liver; grade 2 = intensity 
same with that of the liver; grade 3 = intensity higher than the liver. The FAS is a fatigue questionnaire 
consisting of 10 items; five questions reflecting physical fatigue and five questions for mental fatigue. The 
five point rating scale varies from 1, never, to 5, always. Scores on the FAS can range from 10 to 50.
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Figure 2a. Patient 1with skin involvement of sarcoidosis before treatment 
with adalimumab. The patient gave permission for publishing the photos.
Figure 2b. Patient 1 with cutaneous sarcoidosis after 12 weeks treatment 
with adalimumab.
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IFN-γ decreased slightly in three patients at week 12 (range 6.4-19.0). 
IL-8 levels decreased in three patients at week 12 (range 1.3-31.0). 
These observations did not reach statistical significance. The other 
cytokines were not significantly elevated (data not shown). 
  Clinical symptoms improved in four out of five patients. Improvement 
of fatigue (FAS score 31.0 ± 6.0 before; 22.6 ± 3.6 (P < 0.05) 12 weeks after 
treatment, table 2), was observed. Although not validated by a standardized 
dyspnoea score, four patients noticed a subjective improvement of dyspnoea. 
Discussion 
In this observational study adalimumab treatment proved beneficial within 
12 weeks in four out of five patients with chronically active sarcoidosis. 
Clinical improvement was accompanied by the observation of decreasing 
lysozyme levels and -sarcoid lesions as measured by radiologic and 
scintigraphic techniques. Furthermore serum IFN-γ, IL-8 levels tended 
to correspond with clinical response. To our knowledge, this is the first 
study to relate therapeutic efficacy of adalimumab with several inflammatory 
parameters in a case series of chronic sarcoidosis patients.
  The demonstrated therapeutic efficacy of adalimumab in this study is 
not unexpected, but up till now experience and evidence with adalimumab 
in sarcoidosis is limited in comparison with infliximab. TNF-α blockers, 
such as infliximab, etanercept and adalimumab were successfully introduced
in the treatment of inflammatory disorders more than one decade ago (23). 
Recently, the TNF-α blocker infliximab demonstrated significant clinical 
benefit in large cohorts of patients with pulmonary manifestations of sarcoidosis 
(24, 25). In two double blinded randomized, and placebo controlled trials 
of patients with pulmonary sarcoidosis a favorable clinical response was 
demonstrated (6, 7). Etanercept has been reported effective in case reports, 
but the only trial so far resulted in detoriation of almost a third of the 
patients with acute pulmonary sarcoidosis (26-28). Adalimumab could 
be an important additional option in the treatment with biologicals. 
  There is no consensus regarding timing and duration 
of TNF-α blockers in rheumatological and other inflammatory 
diseases. For example CD patients require higher and more intensive 
treatment schedules of adalimumab than RA patients (29, 30).
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The optimal schedule for TNF-α blockers in sarcoidosis remains unknown, 
according to the case studies, dosages might be similar to those used in CD 
(8, 10). In the current study we initiated a CD schedule and used a relatively 
short observation period of 12 weeks. Hereafter, all patients continued 
adalimumab for at least one year. In this period the patient that initially 
showed a mixed response (patient 4) noted a decrease in disease related 
symptoms, accompanied by improved radiological findings after increasing 
the frequency of administration after 16 weeks (data not shown). This 
observation stresses the importance to adjust dosing and await responses for 
a longer period. Furthermore, this study suggests that an effective schedule 
requires starting with induction of 160 mg, and 80 mg 2 weeks later, followed 
by 40 mg every other week. In case of no immediate –or only moderate 
response, dose –or frequency intensification may be considered. Three years 
after inclusion in this study, three patients (patient 1, 3 and 5) have 
successfully stopped treatment with adalimumab. After 2.5 years the 
response of patient 2 failed, so she switched to infliximab, another TNF-α blocker. 
Patient 4 is still using adalimumab once a week with a mixed response. 
  We have used SRS to evaluate sarcoidosis activity in vivo, although 
18F fluordeoxyglucose (18F-FDG) PET is the classical scintigraphic method. In 
our center we have built up extensive experience with this method in various 
(immune mediated inflammatory) diseases (20). In the current study 18F-FDG 
PET was initially compared to SRS, but appeared not superior (data not shown). 
SRS enabled localization of granulomas by binding to the somatostatin receptors 
that are frequently involved in immune and inflammation responses (20, 31). The 
observations in this study in for example patient 1 (Figure 1), suggest that the 
decrease of the inflammation induced by adalimumab results in less expression 
of somatostatin receptors. Therefore SRS could be a useful imaginary 
technique to monitor organ involvement and therapeutic efficacy in sarcoidosis.
  Many studies on monitoring sarcoidosis have been accomplished, but to 
date no easily applicable marker has emerged. A possible serological marker of 
sarcoidosis activity is sIL-2R (4). This cytokine is considered to reflect T-cell 
activation (32). Cytokines such as IL-2, but also IFN-γ and IL-8 however, are not 
specific for sarcoidosis and might also reflect other inflammatory processes (3).
Grutters et al. described lower serum sIL-2R levels in sarcoidosis patients 
with persistent pulmonary lesions as compared to patients with a 
normalization of their chest x-ray (32). In line with this observation, 
sIL-2R levels and pulmonary lesions persisted in our patients. It might 
therefore be proposed that serum sIL-2R levels do not reflect disease
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activity in patients with chronically active pulmonary sarcoidosis.
Our data suggest that serum IFN-γ and IL-8 levels might be more appropriate in 
this setting. Decreased serum IFN-γ and IL-8 levels tended to correlate with 
radiologic improvement as well as improvement of clinical symptoms. This 
observation adds to the observations by Yokoyama et al. who correlated serum IL-8 
levels with disease activity in 13 out of 16 patients with chronic sarcoidosis (33). 
  In conclusion, this is the first study to demonstrate that adalimumab 
treatment schedule in patients with systemic and chronically active sarcoidosis 
results in a favorable clinical outcome by means of improved radiographic scans, 
a trend of decreased serum cytokine levels and improvement of clinical 
symptoms. 
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General discussion
Sarcoidosis is a fascinating disease with many diverse clinical and 
immunological aspects, making it a challenge to dissect disease 
pathogenesis and to optimize treatment protocols. 
  Thus far the pathophysiology of sarcoidosis is unknown. In 21th 
century, an abundance of studies have demonstrated potential models for the 
pathogenesis. The consensus model states that activated T cells play a crucial 
role in the pathophysiology of sarcoidosis (1). However, all components of the 
immune system can be involved, in this thesis we present for the first time an 
immunopathophysiologal model indicating the importance of B cells in 
sarcoidosis as described in Chapter 2. Moreover, we evaluated new insights 
for diagnostic techniques (Chapter 3) and new treatment 
options in this thesis (Chapter 4). 
 
Pathophysiology
In Chapter 1, the hypothesized model for immunopathogenesis of sarcoidosis 
is presented. Sarcoidosis is considered to be a T cell driven disease with the 
occurrence of noncaseating granulomas (2-4). Granuloma formation is the 
central immunological characteristic in the pathogenesis of sarcoidosis. 
Granulomas are the result of a physiological immunological response to a (low 
antigenic) danger signal and results in the isolation of pathogens the immune 
system itself cannot eliminate. Consequently, granulomas prevent the surrounding 
tissues from continuing inflammatory and damaging effects. The granulomas 
are thought to be formed by an interaction between antigen presenting cells 
(APC) and activated T-lymphocytes, mainly of the CD4 lineage. This inter
action leads to a release of cytokines, especially interleukin (IL)-2 and interferon 
(IFN)-γ. These pro-inflammatory cytokines trigger macrophages to produce 
tumor necrosis factor-α (TNF-α) and strengthen the local inflammation 
response by releasing a cascade of additional cytokines (2, 5). 
  Apart from the APC – T lymphocyte interaction several factors suggest 
that the B cell response in sarcoidosis may be abnormal. These B-cell related 
factors include the occurrence of circulating immune complexes, 
hypergammaglobulinemia, autoantibody production, anergy and reduced 
frequencies of circulating CD27+ memory B cells (6-10). In Chapter 
2, the cellular and molecular characteristics of B cells were 
intensively analyzed in patients with sarcoidosis. The observations 
suggest redistribution of memory B cells towards granulomatous tissue.
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Together with the observation of increased circulating transitional B 
cell numbers and increased molecular signs of antibody maturation, 
this indicates an involvement of an overactive B cell response in the 
pathophysiology of sarcoidosis. Thus, patients with sarcoidosis might 
benefit from B cell directed therapy.
  The results in Chapter 2 demonstrated that plasma cells in 
granulomatous tissue of sarcoidosis patients produce mostly IgA. 
Importantly, IgA-producing plasma cells produce TNF-α, one of the key 
cytokines in the pathogenesis of sarcoidosis (Chapter 4) (11). Unfortunately, 
we were not able to confirm this by stimulation of CD27-IgA+ memory B 
cells, however this could be caused by limited analytical procedures 
(Chapter 2). Moreover, B cells stimulate TNFR2 expression (12). There are 
reports of increased levels of TNFR2 in sarcoidosis patients (13). We did not 
investigate the production of TNFR2 after stimulating B cells, but a hypo
thesis could be that CD27-IgA+ memory B cells are activating the 
expression of TNFR2 which stimulates the production of sarcoid granulomas. 
  The peripheral blood memory B cell compartment is significantly 
affected in patients with sarcoidosis, reduced numbers of natural effector B cells 
and T cell-dependent CD27+IgM+, CD27+IgG+ and CD27+IgA+ memory B cell 
subsets were observed (Chapter 2). Concomitant studies showed low CD27+ 
memory B cells in the blood of patients with severe chronic sarcoidosis (6, 14). 
However, by the use of more detailed analysis of we revealed that this 
impairment is mainly caused by decreased numbers of T cell-dependent memory 
B cells. In contrast, T cell-independent CD27-IgA+ memory B cells are increased 
in sarcoidosis patients. This could explain why the total amount of B cells is 
normal in patients with sarcoidosis. It remains to be determined if the increase 
of T cell-independent B-cell memory directly results from pathogenic B cell 
responses or indirectly to compensate for the loss of other memory B cells. 
  By use of further in depth analyses with detailed molecular analyses of 
IgA and IgG memory B cells we demonstrate increased somatic hypermutations 
levels and immunoglobulin class switching to downstream IgG subclasses in 
patients with sarcoidosis (Chapter 2). These molecular patterns suggest that 
memory B cells in sarcoidosis have been exposed to prolonged specific B cell 
stimulation or consecutive responses (15-17). Thus it is unlikely that sarcoidosis 
patients have defects in the generation of B cell memory, but rather have 
involvement and migration of antigen-experienced B cells towards 
granulomatous tissue.
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We therefore hypothesize that chronic B cell stimulation is related to formation 
of granulomatous tissue in a manner similar as in patients with sarcoidosis-
lymphoma syndrome involving predominantly malignant B cells 
(16, 18-21). It is thought that these B cells undergo malignant 
transformation after chronic stimulation (22). 
  The function of B cells and their role in the formation of granulomas 
is further discussed in Chapter 2. Interestingly, certain patients with 
common variable immunodeficiency (CVID), which is known as a B cell 
differentiation disorder, can develop granulomas and might therefore support 
a theoretical pathophysiological model for sarcoidosis (61, 62). In contrast to 
sarcoidosis, granulomatous CVID patients have hypogammaglobulinemia 
(because of an impaired immunoglobulin production), but have similar reduced 
numbers of blood memory B cells and increased transitional B cells (15, 23, 24). 
We assume that it is unlikely that the decreased numbers of memory B cells are 
a sign of dysfunctional B cell development, because we demonstrate normal 
immunoglobulin responses after vaccination, circulating plasma cell numbers 
and normal serum immunoglobulin levels in sarcoidosis. However, B cells 
seem to be essential for the development of granulomas. This can be learned 
from patients with X-linked agammaglobulinemia (XLA), a distinct form of 
hypogammaglobulinemia characterized by a complete B cell deficiency. These 
XLA patients do not develop granulomas (25). Furthermore, in models of T 
cell deficient mice, it has been shown that B cells are crucial for non-infectious 
granuloma formation (26). Thus, B cells appear to be essential for granuloma 
formation in both antibody-deficient patients and in patients with sarcoidosis. 
Granuloma formation in CVID suggests that immature transitional B cells and 
immature non-switched B cells play a role in granuloma formation. It is of 
particular interest to identify which type of B cell subset is found in the 
granulomatous tissue of CVID patients as compared with sarcoid granuloma (15). 
  Sarcoidosis is thought to be mainly a T-helper (Th)-1 driven disease 
(2). The Th-2 counterpart of this spectrum of diseases is atopy. In order to 
study Th-2 responses clinical Th-1 and Th-2 responses were studied in 
sarcoidosis. We observed a Th-1 preference in sarcoidosis by demonstrating 
the lack of association between atopy and sarcoidosis (Chapter 2). 
Antagonisms between Th-1 and Th-2 axes has been linked to a lower 
prevalence and a less severe course of autoimmune diseases in other studies 
(27). In line with this, we demonstrated in Chapter 2 that atopic eczema was 
negatively associated with uveitis (defined as a Th-1 disease) in sarcoidosis. 
How an eczematous skin may contribute in the protection of physically and 
immunologically isolated eyes is not clear, but may be part of a generally 
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inhibition of Th-2 responses by Th-1. Figure 1 shows a updated version of 
the hypothesized pathogenesis of sarcoidosis with results of this thesis.
Figure 1. Updated version of the hypothesized pathogenesis of 
sarcoidosis with results of this thesis. 
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Diagnostics
Traditionally, sarcoidosis is diagnosed by compatible clinical and conventional 
radiological findings (X-ray and CT scan), the presence of non-caseating 
granulomas and exclusion of similarly presenting disorders (2). In Chapter 3 
we show that the somatostatin receptor scintigraphy (SRS) has added value 
in the diagnostic workup and is more sensitive than conventional imaging 
in sarcoidosis patients. In this longstanding study, all patients with hilar 
and/or mediastinal lymph node involvement observed on chest X-ray or 
CT scan were confirmed by SRS. SRS revealed significantly more thoracic 
lesions than conventional radiologic imaging. Our observations hence 
indicate that the extend of sarcoid disease remains underestimated with 
conventional imaging and underscore the assumption that negative conventional 
imaging for sarcoidosis does not exclude pulmonary involvement. 
  Evaluation of disease activity and therapeutic monitoring is not yet 
standardized. Increased levels of soluble IL-2R (sIL-2R), associated with T cell 
activation, are associated with disease. However, this cytokine receptor is not 
specific for sarcoidosis and increased levels are also found in other inflammatory 
processes (2, 28). Paradoxically low serum sIL-2R levels are described in patients 
with sarcoidosis with persistent pulmonary lesions as compared with patients 
with chest X-ray normalization (29). In line with these observations and lack of 
relevant sIL-2R levels accompanying persistent pulmonary lesions in our study 
presented in chapter 4, we assume that sIL-2R levels do not reflect disease 
activity, at least not in patients with chronically active pulmonary sarcoidosis. 
  Because of the lack of defined disease activity parameters in 
sarcoidosis, peripheral blood biomarkers may be suitable alternatives. ACE 
is a serum factor that is related to the activity of disease in cohort studies, 
but lacks clinical importance in individual patients. It has been demonstrated 
in Chapter 2 that treatment with a TNF-α blocker normalizes the population 
of CD27-IgA+ memory B cells. Suggesting that CD27-IgA+ memory B cell 
numbers could be a potential marker of sarcoidosis activity. Another 
unexpected potential marker for disease activity in sarcoidosis might be 
25-(OH)D levels. In Chapter 4 we described an inverse relation between 
disease activity of sarcoidosis measured by SRS and serum levels of 
25-(OH)D. Recently, other studies have shown that decreased levels of 
serum 25-(OH)D are a risk factor for higher disease activity in several 
inflammatory diseases such as multiple sclerosis and  Crohn’s disease (30-32).
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Therapy
The outcome of sarcoidosis is highly variable. The majority (two-third) of 
patients have spontaneous resolution or show a good response to first-line 
steroid therapy (2, 33). Osteoporosis, diabetes and infections are a few of the many 
effects of corticosteroids (34). Hence, osteoporosis prevention with bisphoshonates 
and/or calcium and vitamin D supplementation is recommended in patients 
using a course of daily 7.5mg prednisone or higher for a period of 3 months or 
longer (35). However, hypercalcemia is described in 5-11% of the sarcoidosis 
patients. Therefore, calcium and vitamin D supplementation is not without risk 
(2, 36, 37). Nevertheless, in Chapter 4 it is demonstrated that supplementation 
of calcium and vitamin D is relatively safe in sarcoidosis patients if there is no 
hypercalcemia at moment of starting the supplementation. Still, hypercalcemia 
can be a consequence of vitamin D therapy and has to be monitored carefully. 
  Sarcoidosis is most frequently diagnosed in the winter months, when 
serum vitamin D levels are at their lowest (38). Thus, when vitamin D 
levels were determined moment of diagnosis, this was mostly done in 
winter. This co-incidence does not explain that lowered vitamin D levels are 
causing sarcoidosis, but the association remains evocative (Chapter 4). If 
indeed decreased levels of serum 25-(OH)D are a potential risk factor for 
higher disease activity in sarcoidosis patients supplementation of vitamin 
D might not only be of prophylactic, but also of therapeutic value.
  There is no defined rational therapy for sarcoidosis. Unfortunately 
a third of the sarcoidosis patients develop a chronic, progressive 
disease which can be refractory to multiple lines of treatment (2). 
Table 1 shows the current immunosuppressive treatment in sarcoidosis. 
  TNF-α inhibition in patients with sarcoidosis has been shown to reduce 
disease signs and symptoms (39). Multiple TNF-blockers have been produced 
and tested in clinical trial. In a phase II, multi-centre, randomized double-blind, 
placebo-controlled study of 138 patients with chronic sarcoidosis, treatment 
with infliximab (chimeric monoclonal antibody against TNF-α) resulted in 
a limited but statistically significant improvement of 2.5% of the predicted 
forced vital capacity (FVC) over placebo (40). Obviously, it has been shown that 
extrapulmonary affected organs show a better response to infliximab (41). 
According to this, golimumab, another monoclonal antibody against TNF-α, 
had no efficacy in pulmonary sarcoid lesions, but trends towards improvement 
in some dermatological end-points is observed (42). Etanercept, another 
TNFα-blocker, has been reported to be effective in several case reports.
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However, the only randomized clinical trial (RCT) with this drug 
showed aggravation of disease in 65% of the patients after (43). Thus, this 
TNFα-blocker has been abandoned in the treatment of sarcoidosis (44-
46). In Chapter 4 we present a case series of five patients with symptomatic, 
chronic, both pulmonary and extra pulmonary sarcoidosis treated 
with adalimumab (human monoclonal antibody against TNF-α). Radiological 
and clinical improvement occurred within 12 weeks. After dose intensivation 
in one patient all patients demonstrated improvement by improved radiological 
images, stressing the importance to adjust dosing in individual patients. 
Table 1. Current immunosuppressive treatment in sarcoidosis.
Medication Dose
Glucocorticosteroids  
Prednisone start 5-40 mg/day
 maintenance <10 mg/day
Anti malaria drugs  
Hydroxychloroquine 200-400 mg/day
Cytotoxic medication  
Azathioprine 50-150 mg/day
Cyclophosphamide 50-150 mg/day oral
 500-1500 mg Q2-4W i.v.
Methothrexate 10-25 mg/weekly
Sodium mycophenolate/mycophenolate mofetil 720mg/1000mg twice daily
Cytokine modulating medication  
Infliximab 5-10 mg/kg Q4-8W
Adalimumab 40- 80 mg Q1-2W  
Thalidomide 50-100 mg/day
TNF-α inhibition in patients with sarcoidosis has been shown to reduce 
disease signs and symptoms (39). Multiple TNF-blockers have been 
produced and tested in clinical trial. In a phase II, multi-centre, randomized 
double-blind, placebo-controlled study of 138 patients with chronic sarcoidosis, 
treatment with infliximab (chimeric monoclonal antibody against 
TNF-α) resulted in a limited but statistically significant improvement of 
2.5% of the predicted forced vital capacity (FVC) over placebo (40). 
Obviously, it has been shown that extrapulmonary affected organs 
show a better response to infliximab (41).
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According to this, golimumab, another monoclonal antibody against TNF-α, 
had no efficacy in pulmonary sarcoid lesions, but trends towards improvement 
in some dermatological end-points is observed (42). Etanercept, another 
TNFα-blocker, has been reported to be effective in several case reports. 
However, the only randomized clinical trial (RCT) with this drug showed 
aggravation of disease in 65% of the patients after (43). Thus, this 
TNFα-blocker has been abandoned in the treatment of sarcoidosis (44-46). In 
Chapter 4 we present a case series of five patients with symptomatic, chronic, 
both pulmonary and extra pulmonary sarcoidosis treated with adalimumab 
(human monoclonal antibody against TNF-α). Radiological and clinical 
improvement occurred within 12 weeks. After dose intensivation in one 
patient all patients demonstrated improvement by improved radiological 
images, stressing the importance to adjust dosing in individual patients. 
  Other potential target cytokines that are involved in the pathogenesis 
of sarcoidosis are IFN-γ (2) (Figure 1) and IL-12. Both are abundant in serum 
and are produced by alveolar macrophages from patients with sarcoidosis (47, 
48). Overexpression of the pro-inflammatory cytokine IL-12 leads to increased 
expression of TNF-α and even more IFN-γ, the key cytokines in the formation 
of granulomas. Therefore, inhibition of IL-12 might have a deteriorating 
effect on granuloma formation. However, a human monoclonal antibody 
(anti-P40) that inhibits IL-12 and IL-23 (ustekinumab), does not exert in a 
clinical beneficial effect in pulmonary sarcoidosis (42). This suggests that 
IL-12 does not has a major role in the pathogenesis of sarcoidosis, or inhibition 
of IL-12 does not resolve the disease once granulomas have been formed. 
  Another possible therapeutic target is IL-6. IL-6 plays a role in the 
production and maintenance of sarcoid granulomas by activation of CD4+ 
T cells (49). Tocilizumab is a monoclonal antibody against IL-6 and could be 
successful in the treatment of sarcoidosis. At the moment tocilizumab is 
successfully used in patients with rheumatoid arthritis (50). However, thus far 
no case reports are known in patients with sarcoidosis of this possible effect. 
  Traditional forms treatment that directly target T cells with drugs such 
as prednisone or methotrexate might be improved by biological modalities. It 
could be of interest to produce a new subtype of these drugs that only tar
gets the cytokines who are responsible for the disturbed T cell response in 
sarcoidosis, consequently keeping the risk of side effects as low as possible. 
As suggested in Chapter 2, also B cells might serve as a therapeutic 
target, e.g. using rituximab, a chimeric monoclonal anti-CD20 antibody (51). 
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CD20 is specifically expressed on the surface of naive and memory B cells but 
not on plasma cells (6). There are a few case reports describing the successful 
use of rituximab in refractory sarcoidosis with lung, eye, lymph nodes and 
skin involvement (52-56). However, the only small but prospective study 
showed inconsistent results (57). It therefore can be concluded that the 
effectiveness of rituximab in chronic sarcoidosis remains a question and 
that further trials are necessary to clarify the exact effect of rituximab 
in sarcoidosis. It is tempting to hypothesize that this may be an 
additional therapeutic option to other current therapies in sarcoidosis. 
  It remains a matter of uncertainty how to monitor the efficacy of 
treatment in sarcoidosis. In chapter 3 and 4 it is shown that SRS may be a 
tool to monitor efficacy of treatment. Unfortunately this does not concern 
patients on steroids (first-line therapy). The somatostatin receptor sub
type 2 (SST2) is highly expressed by sarcoid granulomas and is used as the 
target for SRS (58). Treatment with corticosteroids may downregulate 
SST2 and consequently downgrade uptake of radioactivity in sarcoid 
granulomas (59). 18F-FDG PET scintigraphy has been shown to be related 
to sarcoid activity, however this technique has also its limitations, i.e. 
serum glucose levels and complicated cardiac and brain evaluation (60). 
The new gallium-DOTA-octreotate imager which is suitable for PET 
imaging may be a new alternative. However, radionuclide-coupled 
somatostatin analogues visualize the normal spleen because of an abundant 
SST2 expression by spleen macrophages and endothelium. Combi 
imaging with gallium-DOTA-octreotate and 18F-FDG may be theoretically 
the most sensitive possibility to investigate the extend of sarcoid disease. 
Conclusions 
In this thesis we revealed the possible pathophysiological role for B cells in 
granuloma formation in sarcoidosis. We showed that the B cell function is 
supposed to be normal because the vaccination response is not impaired, 
ruling out a clinical significant humoral immunodeficiency. We showed that 
adalimumab is a promising therapy that results in normalization of specific B 
cell subsets. 25-(OH)D seems to be related to disease activity, supplementation 
of vitamin D is relative safe and successful in decreasing disease activity. 
We showed that extend of disease and therapeutic efficacy can effectively 
be monitored with SRS, a sensitive radio nuclear imaging technique. 
  Sarcoidosis remains a fascinating disease in which various 
immune cells and pathways are involved. The complex pathogenesis results 
in a complex and limited therapeutic approach that needs further 
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development in order to reduce inflammatory activity, decrease side effects and 
improve the quality of life of patients with sarcoidosis. This thesis provides 
new points of action for further research in ‘the disease with many faces’. 
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Summary
Sarcoidosis is a granulomatous disorder of unknown cause affecting multiple 
organs and is characterized by non-caseating granulomas. Usually sarcoidosis 
develops before the age of 50 years, with an incidence peaking at 20 to 39 years. 
The worldwide prevalence varies from 2 to 80 per 100,000. In the Netherlands the 
prevalence is estimated to be 50 per 100,000. However, in 30-60% of the cases the 
prevalence may be underestimated by the asymptomatic signs of the disease.
  Although sarcoidosis was first described in 1877, the pathophysiology 
and what triggers the disease remains still a question. It is presumed that 
granulomas play a central role in the pathogenesis of sarcoidosis. The hypothesis 
in sarcoidosis is that granulomas are formed by an interaction between antigen 
presenting cells and activated T-lymphocytes, mainly CD4+ T cells. This leads 
to a release of cytokines which triggers macrophages to produce TNF-α 
and strengthen the local inflammation response by releasing a cascade of 
several cytokines. In this thesis aspects of sarcoidosis on areas pathophysiology, 
diagnostics and new treatment modalities will be highlighted. 
  In Chapter 2 we revealed the possible pathophysiological role for B 
cells in granuloma formation in sarcoidosis. We observed increased circulating 
transitional B cell numbers and increased molecular signs of antibody maturation, 
which indicates presence of an overactive B cell response. Thus therapy that 
targets B cells might serve as a therapeutic option. Similar to CVID 
patients (an antibody deficiency disorder) we demonstrated reduced numbers 
of blood memory B cells in sarcoid patients. But in contrast to CVID 
patients with granulomas, patients with sarcoidosis have a normal vaccination 
response, making it unlikely that patients with sarcoidosis have impaired 
B cell responses. Furthermore, we demonstrated that treatment with a 
TNF-α blocker normalizes the population of CD27-IgA+ memory B cells 
that we found reduced in untreated patients. Thus, blood CD27-IgA+ 
memory B cell numbers could be a potential marker of sarcoidosis activity. 
  Sarcoidosis is thought to be a mainly Th-1 driven disease. 
We confirmed this by demonstrating the lack of association 
between atopy (a Th-2 driven disease) and sarcoidosis. 
  Traditionally, sarcoidosis is diagnosed by compatible clinical and 
conventional radiological findings (X-ray and CT scan), the presence of 
non-caseating granulomas and exclusion of similarly presenting disorders. In 
Chapter 3 we showed that the SRS has an added value in the diagnostic 
workup and is more sensitive than conventional imaging in sarcoidosis 
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patients. SRS revealed significantly more thoracic lesions than conventional 
radiologic imaging. Our observations hence indicate that the extend of sarcoid 
disease remains underestimated with conventional imaging and underscore the 
assumption that negative conventional imaging for sarcoidosis 
does not exclude pulmonary involvement. 
  Hypercalcemia is described in 5-11% of the sarcoidosis patients. 
Therefore,  calcium and vitamin D supplementation is not without risk. 
Nevertheless we demonstrated in Chapter 4 that supplementation of 
calcium and vitamin D is relatively safe in sarcoidosis 
patients if there is no hypercalcemia at moment of starting 
the supplementation. We also described an inverse relation between 
disease activity of sarcoidosis measured by SRS and serum levels 
of 25-(OH)D. If indeed decreased levels of serum 25-(OH)D are a 
potential risk factor for higher disease activity in sarcoidosis 
patients supplementation of vitamin D might not only be of prophylactic 
(in case of high dosages of corticosteroids), but also of therapeutic value.
  Finally we present data of a case series of five patients with 
symptomatic, chronic, both pulmonary and extra pulmonary sarcoidosis 
treated with adalimumab (TNFα-blocker). Clinical and radiological 
improvement occurred within 12 weeks in four patients. After dose 
intensivation in one patient all patients demonstrated improvement. This 
stresses the importance to adjust dosing of TNFα-blockers in individual patients. 
Chapter 5 contains a general discussion in which the findings 
described in this thesis are put into a broader perspective. In conclusion, 
the studies described in this thesis provided new insights in the 
complex pathophysiology in sarcoidosis and thereby provide possibly new 
parameters for disease activity, diagnostics and targets for treatment. 
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Samenvatting
Sarcoïdose is een multisysteemziekte van onbekende oorzaak en wordt 
gekarakteriseerd door niet-necrotiserende granulomen. Sarcoïdose wordt meest
al gediagnosticeerd vóór het 50e levensjaar met een incidentiepiek tussen de 20 
en 39 jaar. De prevalentie varieert wereldwijd van 2-80 patiënten per 100.000 
inwoners. In Nederland wordt de incidentie geschat op 20 per 100.000 per jaar 
en de prevalentie op 50 per 100.000. Dit is waarschijnlijk een onderschatting, 
omdat de ziekte vaak (bij 30-60% van de patiënten) asymptomatisch verloopt. 
  Sarcoïdose werd voor het eerst in 1877 beschreven, echter is de 
pathofysiologie nog steeds niet duidelijk. Aangenomen wordt dat granulomen een 
centrale rol spelen in de pathofysiologie sarcoïdose. De hypothese is dat bij 
sarcoïdose granulomen gevormd worden door interactie tussen antigeen- 
presenterende cellen en geactiveerde T-lymfocyten, voornamelijk CD4+ T-cellen. 
De hierbij vrijgekomen cytokinen zetten macrofagen aan tot productie van TNF-α 
en versterken de lokale ontstekingsrespons door het vrijkomen van een cascade 
van verschillende cytokinen. In dit proefschrift wordt de pathofysiologie, de 
diagnostische technieken en nieuwe behandelopties bij sarcoïdose besproken. 
  In hoofdstuk 2 laten we de mogelijke pathofysiologische rol van de 
B-cel bij granuloomvorming zien in sarcoïdose patiënten. We hebben ook aan
getoond dat er in sarcoïdose sprake is van een verhoogd aantal circulerende 
transitionele B-cellen en dat de uitrijping van antistoffen verhoogd is. Dit wijst 
op betrokkenheid van een overactieve B-cel respons in de pathofysiologie van 
sarcoïdose met als gevolg dat de B-cel een goed aangrijpingspunt zou zijn voor 
behandelopties. Patiënten met CVID (een antistofdeficiëntie) hebben een 
verlaagd aantal geheugen B-cellen in het perifere bloed wat gelijk is aan onze 
bevindingen bij sarcoïdose patiënten. Echter in tegenstelling tot een subgroep van 
CVID patiënten (patiënten met granulomateuze CVID), laten sarcoïdose 
patiënten wel een normale vaccinatierespons zien. Dit maakt het onwaarschijnlijk 
dat patiënten met sarcoïdose een gestoorde B-cel respons hebben. We hebben 
tevens aangetoond dat na behandeling met een TNF-α remmer het aantal 
CD27-IgA+ geheugen B-cellen normaliseert. Dit suggereert dat CD27-IgA+ 
geheugen B-cellen een mogelijke marker zouden kunnen zijn voor ziekte-activiteit. 
  Van sarcoïdose wordt gezegd dat het voornamelijk een Th-1 
ziekte is. Dit hebben wij bevestigd door de afwezigheid van een 
associatie tussen atopie (een Th-2 gemedieerde ziekte) en sarcoïdose. 
  Sarcoïdose wordt gediagnosticeerd indien er sprake is van 
klinische verschijnselen die compatibel zijn met de ziekte, radiologische 
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afwijkingen (op een thoraxfoto en/of CT-scan) en de aanwezigheid van 
niet-necrotiserende granulomen. Echter dienen andere ziektes wel uitgesloten te 
zijn. In hoofdstuk 3 tonen we aan dat de SMS-scan een toegevoegde waarde 
heeft in de diagnostische work-up bij sarcoïdose. Tevens laten we zien dat deze 
techniek sensitiever is dan conventionele beeldvorming in patiënten met 
sarcoïdose. De SMS-scan toont significant meer pulmonale laesies aan vergeleken 
met conventionele radiologische beeldvorming. Onze observaties suggereren 
daarom dat de uitgebreidheid van de ziekte onderschat wordt met alleen 
conventionele beeldvorming. Daarnaast betekent een niet-afwijkende thoraxfoto 
en/of CT-scan niet dat er geen pulmonale betrokkenheid van de sarcoïdose bestaat. 
  Hypercalciëmie wordt bij 5 tot 11% van de patiënten met sarcoïdose 
beschreven. Daarom is calcium en vitamine D suppletie niet zonder risico. 
Echter tonen wij aan in hoofdstuk 4 dat calcium en vitamine D suppletie 
wel relatief veilig gegeven kan worden, mits er op moment van starten geen 
sprake is van een hypercalciëmie. Daarnaast beschrijven we een omgekeerde 
relatie tussen ziekte-activiteit van sarcoïdose gemeten met de SMS-scan en 
serum waardes van 25-(OH)D. Indien verlaagde waardes van 25-(OH)D 
inderdaad een potentiële risicofactor zijn voor meer ziekte-activiteit in 
sarcoïdose, dan heeft vitamine D suppletie niet alleen een profylactische 
waarde (bij corticosteroïden gebruik), maar ook therapeutisch. 
  Tenslotte presenteren we data van een case serie van vijf patiënten met 
symptomatische, chronisch en zowel pulmonale als niet-pulmonale betrokkenheid 
van de sarcoïdose die behandeld worden met adalimumab (TNF-α remmer). 
Klinische en radiologische verbetering was zichtbaar na 12 weken behandeling 
bij vier van de vijf patiënten. Na het intensiveren van de adalimumab behandeling 
toonde ook de laatste patiënt verbetering. Dit benadrukt het belang dat de 
dosering van TNF-α remmers op de individu aangepast moet worden.
  Hoofdstuk 5 bevat de algemene discussie waarin de resultaten die
beschreven zijn in dit proefschrift in een breder perspectief worden geplaatst.
Concluderend beschrijven onze studies nieuwe inzichten in de complexe 
pathofysiologie van sarcoïdose, nieuwe diagnostische opties en nieuwe 
aangrijpingspunten voor behandeling.  
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En dan ben ik eindelijk toegekomen aan het meest gelezen gedeelte 
van een proefschrift. De afgelopen jaren heb ik met veel plezier aan 
dit proefschrift gewerkt. Uiteraard is dit boekje tot stand gekomen 
met de hulp van anderen, wie ik met dit dankwoord wil bedanken.
Beste Martin. In 2008 leerde ik je kennen als docent van het immunologie 
onderwijs en ik was meteen onder de indruk van je enthousiasme, maar met 
name van al je kennis. Niet veel later ging ik in jouw groep aan de slag als 
onderzoekster en dat als niet-Aziaat. Heel erg bedankt voor al je raad en wijze 
adviezen, ook buiten het werk om. Ik heb altijd erg genoten van onze 
congressen samen. Dat spookhotel in San Antonio zal ik nooit meer vergeten! 
Beste Jan, mijn co-promotor. Ik weet nog goed dat jij mij aan het begin van de 
nacht belde om te vertellen dat ons eerste artikel geaccepteerd was. Jouw 
enthousiasme motiveerde mij om van het volgende artikel ook weer een 
topartikel te maken. En dat lukte! Heel erg bedankt voor je hulp de afgelopen jaren. 
Beste Menno. Opeens kreeg je er een promovenda uit de kliniek bij. Ik 
ben vereerd dat jij mijn co-promotor wilde zijn. Jouw kennis en deename
aan de klinische onderzoeken heb ik altijd erg gewaardeerd. 
Jouw aanvullingen waren zeer waardevol en tilden de artikelen en ook 
dit proefschrift naar een hoger niveau. Veel succes in Melbourne. 
Paul, Virgil, Jasper, Kiki, Marianne, Kim, Leendert, Jeroen en Wim, dank voor 
jullie steun, gezelligheid en de leuke congressen die we samen hebben gehad. 
Benjamin en Edwin heel erg bedankt voor al jullie hulp bij de analyses op het lab. 
Edwin jij was in begin mijn grote steun op het lab, ik kon echt alles aan je vragen 
en je was altijd bereid om mij te helpen en mee te denken. Benjamin, jij nam 
later de taak van Edwin over, ik waardeer het zeer dat je zelfs je vrije dagen opgaf 
om mij te kunnen helpen bij de analyses. Het is gelukkig niet voor niets geweest!
Beste Judy, ook jij heel erg bedankt voor je hulp (met name met al het papierwerk). 
Het jaar dat we samen een kamer deelden op de D-vleugel heb ik als een erg leuke 
tijd ervaren en ons reisje naar New York was natuurlijk helemaal onvergetelijk!
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Femke en WaiKwan, ook jullie wil ik bedanken. Jullie namen mij als 3e jaars 
geneeskunde studente onder jullie hoede en hebben mij enthousiast gemaakt
om door te gaan met wetenschappelijk onderzoek, zie hier het eindresultaat! 
Beste professor Hoogsteden, bedankt voor de opleidingsplek tot longarts die je mij 
aanbood. Ik kijk uit naar het verdere vervolg van deze opleiding op jouw afdeling. 
Dr. van den Toorn, mijn opleider in het Erasmus MC en dr. Rietveld, 
mijn oud-opleider in het Sint Franciscus Gasthuis, ook jullie wil ik bedanken 
voor de steun en begrip de afgelopen jaren. Ik wil al mijn (oud) collega’s uit Sint 
Franciscus Gasthuis en het Erasmus MC bedanken voor de steun 
tijdens deze promotie. 
Eva, Laura, Chang, Stefanie en Dorien, heel erg bedankt voor jullie 
motiverende gesprekken en goede adviezen als ik het even niet 
meer zag zitten. Ik hoop dat we nog veel leuke dingen samen gaan 
doen. En Dorien misschien komt er ooit nog wel een doliboka!
Joost, Anja en Nieke ook jullie wil ik bedanken. Bedankt voor de steun 
bij de afronding van het proefschrift en zeker de inspiratie voor 
de omslag! Dat we samen nog veel gezellige dagen gaan beleven.
Susan! Wat ben ik blij dat je vandaag naast me staat als paranimf. 
Lieve Oma, ik zeg al een hele tijd tegen jou dat ik binnenkort ga 
promoveren en dat je daar absoluut bij moet zijn. Het is een paar keer 
spannend geweest of dat voor jou nog wel zou lukken, maar gelukkig is 
het nu zo ver. Ik ben blij dat ik deze dag samen met jou mee mag maken!
Papa en mama, ook al is het soms niet makkelijk dat we niet dicht bij elkaar 
wonen, maar jullie staan altijd voor me klaar en hebben me gesteund in al 
mijn keuzes. Dank jullie wel daarvoor! Ik ben trots dat ik jullie dochter ben. 
Brian, ondanks dat jij zelf moeilijke jaren hebt doorgemaakt en we elkaar niet 
vaak zien, heb je mij altijd gesteund en maak je mij weer aan het lachen 
(of ik jou…). Ik ben dan ook erg trots dat jij mijn paranimf bent vandaag! 
Lieve Sander, bedankt voor je steun en dat je er altijd voor me bent. Jouw liefde 
en humor zijn van onschatbare waarde geweest. Ik kijk uit naar onze toekomst 
samen. Ik hou van jou!!
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